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METHODS AND COMPOSITIONS FOR 
VACCNATION OF ANIMALS WITH PRRSV 
ANTIGENS WITH IMPROVED 
IMMUNOGENICITY 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims priority to U.S. Provisional Patent 
Application No. 60/712.357, filed on Aug. 30, 2005. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH ORDEVELOPMENT 
This invention was made with Government Support under a 
National Research Initiative Competitive Grant #2004-01576 
from the U.S. Department of Agriculture and under a 
National Institute of Health COBRE program of the National 
Center for Research Resources Project #P20RR 15636. The 
government has certain rights to this invention. 
APPENDIX 
Not Applicable 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
This invention relates generally to compositions compris 
ing Porcine Reproductive and Respiratory Syndrome Virus 
(PRRSV) antigens with improved immunogenicity and meth 
ods for their use. The compositions and methods described 
herein result in improved immunogenic responses of pigs to 
PRRSV antigens, thus providing for improved protection of 
pigs to PRRSV infection. 
2. Related Art 
PRRSV is an economically important pathogen that affects 
pigs. Infection of sows and gilts with PRRSV can result in 
reproductive failure. PRRSV also causes respiratory disease 
in pigs of allages. It is possible to vaccinate the pigs to protect 
them from infection with PRRSV. However, the current com 
mercially available vaccines (most of which are live attenu 
ated vaccines) are somewhat ineffective and therefore should 
be improved. The complete immunologic mechanisms of 
protection against PRRSV are not clear; however, it has been 
clearly shown that PRRSV-neutralizing antibodies are central 
to this protection. Unfortunately, the PRRSV itself (in its 
wild-type form) or the current live vaccines derived from it 
have poor ability to induce virus-specific neutralizing anti 
bodies in a timely manner and at effective (i.e., protective) 
levels. 
U.S. Pat. No. 6,500,662, “Infectious cDNA clone of North 
American porcine reproductive and respiratory syndrome 
(PRRS) virus and uses thereof (by Calvert et al., Dec. 31, 
2002) describes the development of an infectious North 
American PRRSV cDNA clone and its use as a vaccine. 
However, U.S. Pat. No. 6,500,662 does not disclose PRRSV 
vaccines that comprise hypoglycosylated PRRSV antigens. 
In another study, sequences of the GP5 protein (or ORF5 
protein) from various North American PRRSV strains were 
compared to one another and to the representative European 
PRRSV isolate known as the Lelystad strain, revealing that 
the N-linked glycosylation sites at Asparagine 44 (N44) and 
Asparagine 51 (N51) of the GP5 consensus sequence were 
conserved in all of the PRRSV isolates examined (Pirzadeh et 
al., Can. J. Vet Res., 1998, 62:170-177). However, the N-gly 
cosylation site located at Asparagine 31 (N31) of the GP5 
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consensus sequence was absent in certain North American 
PRRSV isolates and absent in the European PRRSV Lelystad 
strain isolate. Recombinant GST-GP5 fusion proteins from 
four (4) North American PRRSV strains and the Leylstad 
strain were produced in E. coli as insoluble inclusion bodies, 
renatured, and used as immunogens in rabbits. Such recom 
binant proteins produced in E. coli retain but do not glycosy 
late their native N-glycosylation sites. 
Inoculation of pigs with a DNA vaccine comprising a 
CMV promoterfusion to the GP5 gene of the IAF-Klop North 
American PRRSV isolate has also been shown to provide 
protection in immunized animals against PRRSV challenge 
(Pirzadeh and Dea, 1998, J. General Virology, 79,989-999). 
This particular GP5 gene isolate encodes a GP5 protein con 
taining the N31, N44 and N51 Asparagine residues that are 
presumably glycosylated when expressed in pigs immunized 
with the DNA vaccine. Vaccination of pigs with E. coli pro 
duced GST-GP5, which retain but do not glycosylate the 
native N-glycosylation sites of the GP5 gene of the IAF-Klop 
strain, did not protect the lungs of virus-challenged pigs. 
European PRRSV infectious clones containing mutations 
that result in expression of hypoglycosylated PRRSV pro 
teins have also been described (Wissink et al., 2004, J. Gen. 
Virol. 85:3715-23). This particular reference reports that 
PRRSV containing mutations in the Asparagine Residue 53 
(N53) of the PRRSV Lelystad strain GP(5) protein that pre 
vent N-linked glycosylation of that site are infectious and can 
produce infectious PRRSV Lelystad strain virus particles. In 
contrast, PRRSV containing mutations in the N46 of the 
PRRSV Lelystad strain GP(5) protein that prevent N-linked 
glycosylation of that site are not infectious and do not produce 
infectious PRRSV Lelystad strain virus particles. Wissink et 
al. speculate that N-glycan sites in the European PRRSV 
GP protein, and, by analogy, the N53 site of the GP5 pro 
tein, could act at many different levels in the natural host, 
including receptor interactions or immune shielding. 
In viruses other than PRRSV, glycan residues have been 
implicated in a variety of roles. The N-linked glycosylation, 
in general, is important for correct folding, targeting, and 
biological activity of proteins (Helenius, A. and M. Aebi. 
Annu. Rev. Biochem. 73:1019-1049, 2004; Williams, D. B. 
and GlycoconjJ., 12:iii-iv, 1995; Zhang, et al., Glycobiology 
14:1229-46, 2004). In many enveloped viruses, the envelope 
proteins are modified by addition of Sugar moieties and the 
N-linked glycosylation of envelope protein plays diverse 
functions of viral glycoproteins such as receptor binding, 
membrane fusion, penetration into cells, and virus budding 
(Braakman, I. and E. van Anken, Traffic 1:533-9, 2000: Doms 
et al. Virology 193:545-62, 1993). Recent studies have dem 
onstrated the role of N-linked glycosylation of Hantaan virus 
glycoprotein in protein folding and intracellular trafficking 
(Shi, X. and R. M. Elliott, J. Virol. 78:5414-22, 2004) as well 
as in biological activity and antigenicity of influenza virus 
hemagglutinin (HA) protein (Abe.Y., et al., J. Virol. 78:9605 
11, 2004). Furthermore, it has become evident that glycosy 
lation of viral envelope proteins is a major mechanism for 
viral immune evasion and persistence used by several differ 
ent enveloped viruses to escape, block or minimize the virus 
neutralizing antibody response. Examples of this effect have 
been reported for SIV (Reitter, J. N. et al., Nat. Med. 4:679 
84, 1998) and HIV-1 (Wei, X. et al., Nature 422:307-12, 
2003), HBV (Lee, J. et al. Biochem. Biophys. Res. Commun. 
303:427-32, 2003), influenza (Skehel, J.J. et al., Proc. Natl. 
US 7,608,272 B2 
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Acad. Sci. USA 81:1779-83, 1984) and the arterivirus LDV 
(Chen, Z. et al. Virology 266:88-98, 2000). 
SUMMARY OF THE INVENTION 
It is in view of the above problems that the present inven 
tion was developed. It is demonstrated that hypoglycosylated 
variants of a PRRSV major surface protein GP5 increased the 
level of PRRSV-neutralizing antibodies produced by immu 
nized pigs relative to the levels of neutralizing antibodies 
produced by pigs immunized with wild type (wt) or glycosy 
lated GP5. 
This invention first provides for a method of eliciting an 
improved immune response in a pig to a Porcine Reproduc 
tive and Respiratory Syndrome Virus (PRRSV) antigen, com 
prising the administration of a composition comprising a 
polynucleotide encoding a hypoglycosylated PRRSV GP5 
polypeptide variant wherein at least one N-linked glycosyla 
tion site corresponding to asparagine 34 or asparagine 51 in a 
reference GP5 protein of SEQ ID NO:1 is inactivated. In 
certain embodiments of the method, at least one N-linked 
glycosylation site corresponding to asparagine 34 or aspar 
agine 51 in SEQID NO:1 is inactivated. This polynucleotide 
can comprise an infectious PRRSV RNA molecule or a DNA 
molecule that encodes an infectious PRRSV RNA molecule. 
The infectious PRRSV RNA molecule is a North American 
PRRSV derivative or a European PRRSV derivative. Alter 
natively, this polynucleotide can comprise a DNA molecule 
wherein a promoter active in mammalian cells is operably 
linked to said polynucleotide encoding a hypoglycosylated 
GP5 protein. This promoter is a CMV promoter in certain 
preferred embodiments of the invention. Alternatively, the 
polynucleotide can be a viral vector. Representative viral 
vectors that can be used include vaccinia virus vectors, a 
herpes simplex viral vectors, adenovirus vectors, alphavirus 
vectors, and TGEV vectors. 
A variety of types and sources of PRRSV sequences can be 
used to obtain the polynucleotide encoding a hypoglycosy 
lated PRRSV GP5 polypeptide variant wherein at least one 
N-linked glycosylation site corresponding to asparagine 34 or 
asparagine 51 in a reference GP5 protein of SEQID NO.1 is 
inactivated. In certain embodiments of the invention, a poly 
nucleotide encoding a hypoglycosylated PRRSV GP5 
polypeptide variant is obtained by direct synthesis, mutagen 
esis of a North American PRRSV isolate GP5 nucleotide 
sequence or mutagenesis of a consensus North American 
PRRSV GP5 nucleotide sequence. The North American 
PRRSV isolate GP5 nucleotide sequence can be selected 
from the group of nucleotides that encode the GP5 proteins of 
SEQID NO:1, SEQID NO:2, SEQID NO:3, SEQID NO:4, 
SEQID NO:5, SEQID NO:6, SEQID NO:7, SEQID NO:8, 
SEQ ID NO:9, SEQ ID NO:10, SEQID NO:11, SEQ ID 
NO:12, and SEQID NO:13. The consensus North American 
PRRSV GP5 nucleotide sequence encodes a consensus GP5 
protein that is at least 85% identical to SEQID NO:14. In 
other embodiments of the invention, the polynucleotide 
encoding a hypoglycosylated PRRSV GP5 polypeptide vari 
antis obtained by direct synthesis, mutagenesis of a European 
PRRSV isolate GP5 nucleotide sequence or mutagenesis of a 
consensus European PRRSV GP5 nucleotide sequence. The 
European PRRSV isolate GP5 nucleotide sequence encodes a 
GP5 protein that is at least 85% identical to SEQID NO:15. 
A variety of methods of inactivating specified N-linked 
glycosylation sites can be used to effectively practice the 
method of this invention. One preferred method of inactivat 
ing an N-linked glycosylation site corresponding to aspar 
agine 51 is to replace the asparagine codon with a codon 
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encoding an amino acid other than asparagine. This replace 
ment codon can encode analanine or a glutamine residue. In 
more preferred embodiments, both of said N-linked glycosy 
lation sites corresponding to asparagine 34 and asparagine 51 
in a reference GP5 protein of SEQIDNO:1 are inactivated. In 
other embodiments, the N-linked glycosylation site corre 
sponding to asparagine 34 is inactivated. This asparagine 34 
N-linked glycosylation site can be inactivated by replacing a 
codon encoding said asparagine 34 with a codon encoding an 
amino acid other than asparagine. The codon encoding 
another amino acid can encode an alanine or a glutamine 
residue. In other preferred embodiments, both of the N-linked 
glycosylation sites corresponding to asparagine 34 and aspar 
agine 51 in a reference GP5 protein can be inactivated by 
replacing codons encoding the asparagine 34 and the aspar 
agine 51 with codons encoding an amino acid other than 
asparagine. Both codons encoding the asparagine 34 and the 
asparagine 51 can be replaced with codons encoding eitheran 
alanine or a glutamine residue to inactivate those glycosyla 
tion sites. Alternatively, both codons can be replaced with 
codons that encode analanine residue to inactivate both gly 
cosylation sites. Alternatively, one of the N-linked glycosy 
lation sites is inactivated by replacing one codon encoding 
said asparagine 34 or said asparagine 51 with a codon encod 
ing an amino acid other than asparagine while the other 
N-linked glycosylation site is inactivated by other techniques. 
In preferred embodiments, the method employs an infec 
tious PRRSV RNA molecule that is a North American 
PRRSV derivative encoding a hypoglycosylated PRRSV 
GP5 polypeptide variant protein wherein at least one 
N-linked glycosylation site corresponding to asparagine 34 or 
asparagine 51 in a reference GP5 protein of SEQID NO:1 is 
inactivated. In more preferred embodiments, both of said 
N-linked glycosylation sites corresponding to asparagine 34 
and asparagine 51 in a reference GP5 protein of SEQID NO:1 
are inactivated. Both of the N-linked glycosylation sites cor 
responding to asparagine 34 and asparagine 51 in a reference 
GP5 protein can be inactivated by replacing codons encoding 
the asparagine 34 and the asparagine 51 with codons encod 
ing an amino acid other than asparagine. Both codons encod 
ing the asparagine 34 and the asparagine 51 can be replaced 
with codons encoding either analanine or a glutamine residue 
to inactivate those glycosylation sites. Alternatively, both 
codons can be replaced with codons that encode an alanine 
residue to inactivate that glycosylation site. 
To practice this method, the polynucleotide containing 
composition is administered by subcutaneous injection, intra 
venous injection, intradermal injection, parenteral injection, 
intramuscular injection, needle free injection, electropora 
tion, oral delivery, intranasal delivery, oronasal delivery, or 
any combination thereof. The administered composition can 
further comprise a therapeutically acceptable carrier. This 
therapeutically acceptable carrier is selected from the group 
consisting of a protein, a buffer, a surfactant, and a polyeth 
ylene glycol polymer, or any combination thereof. 
The administered composition can further comprise an 
adjuvant. This adjuvant can be aluminum hydroxide, Quil A. 
an alumina gel suspension, mineral oils, glycerides, fatty 
acids, fatty acid by-products, mycobacteria, and CpG oli 
godeoxynucleotides, or any combination thereof. The admin 
istered composition can also comprise a second adjuvant Such 
as interleukin 1 (IL-1), IL-2, IL4, IL-5, IL6, IL-12, gamma 
interferon (g-IFN), cell necrosis factor, MDP (muramyl 
dipeptide), immuno stimulant complex (ISCOM), and lipo 
SOCS. 
The improved immune response of a pig to a PRRSV 
antigen can comprise increased production of PRRSV neu 
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tralizing antibodies by said pig. Increased production of 
PRRSV neutralizing antibodies is typically observed upon 
immunization of the pig by the methods and compositions of 
this invention. The improved immune response can be 
obtained in a Sow, a gilt, a boar, or a piglet. 
The invention also provides a method of eliciting an 
improved immune response in a pig to a Porcine Reproduc 
tive and Respiratory Syndrome Virus (PRRSV) antigen, com 
prising the administration of a composition comprising a 
hypoglycosylated PRRSV GP5 polypeptide variant wherein 
at least one N-linked glycosylation site corresponding to 
asparagine 34 or asparagine 51 in a reference GP5 protein of 
SEQ ID NO:1 is inactivated to said pig. Hypoglycosylated 
PRRSV GP5 polypeptide variant protein can be produced by 
the same polynucleotides used in the previously described 
methods in bacterial, yeast, or mammalian expression sys 
temS. 
The instant invention also provides for compositions com 
prising a polynucleotide encoding a hypoglycosylated North 
American PRRSV GP5 polypeptide variant wherein at least 
one N-linked glycosylation site corresponding to asparagine 
51 in a reference GP5 protein of SEQID NO:1 is inactivated, 
and a therapeutically acceptable carrier. In certain embodi 
ments, the compositions comprise polynucleotides where 
both N-linked glycosylation sites corresponding to aspar 
agine 34 and asparagine 51 in SEQID NO:1 are inactivated. 
In preferred embodiments, this composition can comprise 
either an infectious North American PRRSV RNA molecule 
or a DNA molecule that encodes an infectious North Ameri 
can PRRSV RNA molecule. In other embodiments, the poly 
nucleotide comprises a DNA molecule wherein a promoter 
active in mammalian cells is operably linked to said poly 
nucleotide encoding said hypoglycosylated North American 
PRRSV GP5 polypeptide variant. In certain preferred 
embodiments, this promoter is a CMV promoter. In still other 
embodiments, the polynucleotide in the composition com 
prises a viral vector. Viral vectors that can be used in the 
composition can be any one of a vaccinia virus vector, a 
herpes simplex viral vector, an adenovirus vector, an alphavi 
rus vector, and a TGEV vector. 
In the polynucleotides of the composition, an N-linked 
glycosylation site is inactivated by replacing a codon encod 
ing said asparagine 51 with a codon encoding an amino acid 
other than asparagine. The codon encoding an amino acid 
other than asparagine encodes an alanine or a glutamine resi 
due. In other embodiments of this composition, an additional 
N-linked glycosylation site is inactivated by replacing a 
codon encoding asparagine 34 with a codon encoding an 
amino acid other than asparagine. This codon encoding 
another amino acid can encode an alanine or a glutamine 
residue. Preferred compositions comprising polynucleotides 
encoding a hypoglycosylated North American PRRSV GP5 
polypeptide variant protein wherein both of said N-linked 
glycosylation sites corresponding to asparagine 34 and aspar 
agine 51 in a North American reference GP5 protein of SEQ 
ID NO:1 are inactivated are thus provided for by this appli 
cation. Both of the said N-linked glycosylation sites can be 
inactivated by replacing codons encoding said asparagine 34 
and said asparagine 51 with codons encoding an amino acid 
other than asparagine. These codons encoding an amino acid 
other than asparagine can encode either an alanine or a 
glutamine residue. 
The therapeutically acceptable carrier used in the compo 
sition can be a protein, a buffer, a Surfactant, and a polyeth 
ylene glycol polymer, or any combination thereof. The com 
position further comprises at least one adjuvant. 
10 
15 
25 
30 
35 
40 
45 
50 
55 
60 
65 
6 
This adjuvant can be aluminum hydroxide, Quil A, an 
alumina gel Suspension, mineral oils, glycerides, fatty acids, 
fatty acid by-products, mycobacteria, and CpG oligodeoxy 
nucleotides, or any combination thereof. The composition 
can further comprise a second adjuvant selected from the 
group consisting of interleukin 1 (IL-1). IL-2, IL4, IL-5, IL6. 
IL-12, gamma interferon (g-IFN), cell necrosis factor, MDP 
(muramyl dipeptide), immuno stimulant complex (ISCOM), 
and liposomes. 
A composition comprising a hypoglycosylated North 
American PRRSV GP5 polypeptide variant wherein at least 
one N-linked glycosylation site corresponding to asparagine 
51 in a reference GP5 protein of SEQID NO:1 is inactivated 
and a therapeutically acceptable carrier is also provided by 
this invention. In preferred embodiments, N-linked glycosy 
lation sites corresponding to both asparagine 34 or asparagine 
51 in a reference GP5 protein of SEQ ID NO:1 are inacti 
vated. Hypoglycosylated PRRSV GP5 polypeptide variant 
protein can be produced by the same polynucleotides used in 
the previously described methods in bacterial, yeast, or mam 
malian expression systems. 
The instant invention also provides isolated polynucle 
otides encoding a hypoglycosylated North American PRRSV 
GP5 polypeptide variant wherein at least one N-linked gly 
cosylation site corresponding to asparagine 51 in a reference 
GP5 protein of SEQ ID NO:1 is inactivated. In certain 
embodiments, polynucleotides where both N-linked glycosy 
lation sites corresponding to asparagine 34 and asparagine 51 
in SEQ ID NO:1 are inactivated are provided. In preferred 
embodiments, this isolated polynucleotide can comprise 
either an infectious North American PRRSV RNA molecule 
or a DNA molecule that encodes an infectious North Ameri 
can PRRSV RNA molecule. In other embodiments, the iso 
lated polynucleotide comprises a DNA molecule wherein a 
promoteractive in mammalian cells is operably linked to said 
polynucleotide encoding said hypoglycosylated North 
American PRRSV GP5 polypeptide variant. In certain pre 
ferred embodiments, this promoter is a CMV promoter. In 
still other embodiments, the isolated polynucleotide com 
prises a viral vector. Viral vectors that can be used in the 
composition can be any one of a vaccinia virus vector, a 
herpes simplex viral vector, an adenovirus vector, an alphavi 
rus vector, and a TGEV vector. 
In the isolated polynucleotides an N-linked glycosylation 
site is inactivated by replacing a codon encoding said aspar 
agine 51 with a codon encoding an amino acid other than 
asparagine. The codon encoding an amino acid other than 
asparagine encodes analanine or a glutamine residue. In other 
preferred embodiments, an additional N-linked glycosylation 
site is inactivated by replacing a codon encoding asparagine 
34 with a codon encoding an amino acid other than aspar 
agine. This codon encoding anotheramino acid can encode an 
alanine or a glutamine residue. Preferred polynucleotides 
encoding a hypoglycosylated North American PRRSV GP5 
polypeptide variant protein wherein both of said N-linked 
glycosylation sites corresponding to asparagine 34 and aspar 
agine 51 in a North American reference GP5 protein of SEQ 
ID NO:1 are inactivated are thus provided. Both of the said 
N-linked glycosylation sites can be inactivated by replacing 
codons encoding said asparagine 34 and said asparagine 51 
with codons encoding an amino acid other than asparagine. 
These codons encoding an amino acid other than asparagine 
can encode either an alanine or a glutamine residue. 
The invention also provides for an isolated polypeptide that 
is a hypoglycosylated North American PRRSV GP5 polypep 
tide variant wherein at least one N-linked glycosylation site 
corresponding to asparagine 51 in a reference GP5 protein of 
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SEQID NO:1 is inactivated. The isolated hypoglycosylated 
PRRSV GP5 polypeptide variant protein can be produced by 
the same polynucleotides used in the previously described 
methods in bacterial, yeast, or mammalian expression sys 
tems and purified by chromatography or other techniques. 
Further features and advantages of the present invention, as 
well as the structure and operation of various embodiments of 
the present invention, are described in detail below with ref 
erence to the accompanying drawings. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The accompanying drawings, which are incorporated in 
and form a part of the specification, illustrate the embodi 
ments of the present invention and together with the descrip 
tion, serve to explain the principles of the invention. In the 
drawings: 
FIG. 1 illustrates the transient Expression of PRRSV GP5 
and M protein. A. Schematic of the bicistronic construct 
showing the GP5 and M coding regions flanking the IRES 
(IE) from encephalomyocarditis virus. The coding regions 
are under the control of T7 RNA polymerase promoter (black 
rectangle) present immediately upstream of the GP5 coding 
region. The bent arrow shows the position and direction of 
transcription by T7 RNA polymerase from the vector. B. 
Expression of GP5 and M proteins in cells transfected with 
the bicistronic vector. Mock-transfected (lane 1) or plasmid 
transfected cells (lanes 2-7) were radiolabeled as described in 
Materials and Methods, immunoprecipitated with anti-Gp5 
antibody (lanes 1-5) or anti-Mantibody (lanes 6-7). Immu 
noprecipitated proteins were left untreated (-) (lanes 1, 2, 6. 
and 7) or treated (+) with Endo H(lane 3), PNGase F (lane 4) 
and analyzed by electrophoresis. Lane 5 contains immuno 
precipitated proteins from transfected cells treated (+) with 
tunicamycin. Mobility of proteins with relative molecular 
mass (Mr) in kilodaltons are shown. 
FIG. 2 illustrates the glycosylation analysis of WTGP5 
and its mutants using a bicistronic plasmid. A. Schematic of 
the bicistronic vector and the PRRSV GP5 with the three 
putative glycosylation sites atamino acid positions 34, 44 and 
51 shown. B. Various mutants used in the present study. C. 
Expression of wt and mutant GP5 and their sensitivity to 
Endo H. The experiment was performed as described in the 
legend to FIG. 1, proteins were immunoprecipitated with 
anti-GP5 antibody, digested with Endo H (+) or left undi 
gested (-) and analyzed by electrophoresis. Mutant GP5 pro 
teins are shown by arrowheads. Mobility of proteins with 
relative molecular mass (Mr) in kilodaltons are shown on 
right. 
FIG. 3 illustrates the characterization of mutant viruses 
encoding mutant GP5. A. Single step growth kinetics of wt 
(FL-12) and various mutant PRRSVs in MARC-145 cells. 
Cells in six-well plated were infected with PRRSVatan MOI 
of 3, culture supernatants were collected at indicated times 
after infection and virus titers were determined. Average titers 
with standard deviation (error bars) from three independent 
experiments are shown. B. Plaque morphology of mutant 
viruses. Open arrows and arrowheads show plaques that are 
less clear. C. Trans-complementation to recover mutant 
PRRSVs. Quantitative analysis of mutant virus recovery from 
cells expressing wt GP5 protein. Average yield of viruses 
from three independent experiments with standard deviation 
(represented by error bars) is shown. 
FIG. 4 illustrates an examination of GP5 incorporated into 
mutant virions and synthesized in mutant virus-infected cells. 
A. Radiolabeled virions from culture supernatants of infected 
cells were pelleted, GP5 protein was immunoprecipitated, 
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treated with (+) or without (-) Endo H and analyzed by 
electrophoresis. GP5 with and without Endo H digestion in 
lanes 1 and 2 are shown by white brackets. B. Cells infected 
with various mutant viruses were radiolabeled, GP5 was 
immunoprecipitated, treated with (+) or without (-) Endo H 
and analyzed by electrophoresis. GP5 with and without Endo 
H digestion in lanes 2 and 3 are shown by white brackets. 
Mobility of proteins with relative molecular mass (Mr) in 
kilodaltons are shown on right side of each panel. 
FIG.5 illustrates an alignment of North American PRRSV 
GP5 n-terminal amino acid sequences with the North Ameri 
can PRRSV GP5 reference n-terminal sequence (SEQ ID 
NO:1; strain NVSL 97-7895). The first 60 N-terminal amino 
acids of an alignment of the 200 amino acid proteins are 
shown. The asparagine 34“NSS and asparagine 51 “NGT 
N-linked glycosylation sites in the proteins are shown in bold. 
Other N-linked glycosylation sites located between residues 
29 and 35 of the reference GP5 protein are underlined. 
FIG. 6 illustrates an alignment of European PRRSV GP5 
N-terminal amino acid sequence with the North American 
PRRSV GP5 reference n-terminal sequence (SEQID NO:1; 
strain NVSL 97-7895). An alignment of the entire GP5 pro 
tein of approximately 200 amino acid proteins is shown 
where the asparagine 51 “NGT N-linked glycosylation site 
in the proteins is shown in bold (i.e., asparagine 53 in SEQID 
NO:15). 
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
Definitions 
Acceptable carrier, as used herein, refers to a carrier that 
is not deleterious to the other ingredients of the composition 
and is not deleterious to material to which it is to be applied. 
“Therapeutically acceptable carrier refers to a carrier that is 
not deleterious to the other ingredients of the composition and 
is not deleterious to the human or other animal recipient 
thereof. In the context of the other ingredients of the compo 
sition, “not deleterious' means that the carrier will not react 
with or degrade the other ingredients or otherwise interfere 
with their efficacy. Interference with the efficacy of an ingre 
dient does not encompass mere dilution of the ingredient. In 
the context of the animal, “not deleterious' means that the 
carrier is not injurious or lethal to the plant or animal. 
'Adjuvant, as used herein, refers to any material used in 
conjunction with an antigen that enhances the ability of that 
antigen to induce an immune response. 
Administration’, as used herein, refers to any means of 
providing a polynucleotide, a polypeptide or composition 
thereof to a subject. Non-limiting examples of administration 
means include Subcutaneous injection, intravenous injection, 
intradermal injection, parenteral injection, intramuscular 
injection, needle free injection, electroporation, oral delivery, 
intranasal delivery, oronasal delivery, or any combination 
thereof. 
"Antigen', as used herein, refers to any entity that induces 
an immune response in a host. 
“Consensus sequence', as used herein, refers to an amino 
acid, DNA or RNA sequence created by aligning two or more 
homologous sequences and deriving a new sequence that 
represents the common amino acid, DNA or RNA sequence. 
“Hypoglycosylated PRRSV GP5 polypeptide variant', as 
used herein, refers to PRRSV GP5 proteins wherein the origi 
nal or non-variantamino acid sequence that comprises one or 
more N-linked glycosylation sites has been changed so as to 
reduce the number of N-linked glycosylation sites in the 
US 7,608,272 B2 
resultant GP5 variant protein. Under this definition, expres 
sion of an original or non-variant GP5 protein in E. coli to 
produce a GP5 protein with the original GP5 sequence con 
taining the same number of glycosylation sites would not 
result in production of a hypoglycosylated PRRSV GP5 
polypeptide variant. 
“Immune response', as used herein, refers to the produc 
tion of antibodies and/or cells (such as T lymphocytes) that 
bind, degrade or otherwise inhibit, a particular antigen. 
Related phrases such as “an improved immune response' 
refer to the use of the methods and compositions that result in 
any measurable improvement in the response of an immu 
nized host to an antigen. For example, measurable improve 
ments in an immune response include, but are not limited to, 
increased production of neutralizing antibodies (i.e., 
increased antibody titers) relative to the levels of production 
observed in control animals that have been immunized with 
antigens that lack the structural modifications that provide for 
an improved immune response. 
"Infectious RNA molecule” refers to an RNA molecule 
that encodes all necessary elements for production of a func 
tional virion when introduced into a permissive host cell. 
"Infectious clone', as used herein, refers to a DNA mol 
ecule that encodes an infectious RNA molecule. 
“North American PRRSV, as used herein, refers to any 
PRRSV comprising polynucleotide sequences associated 
with a North American PRRSV isolates, such as, but not 
limited to, the NVSL 97-7895 strain (Truong etal, Virology, 
325:308-319 and references contained therein) or IAF-Klop, 
MLV, ATCC VR-2332, ATCC VR-2385, IAF-BAJ, IAF 
DESR, IAF-CM, IAF 93-653, IAF 93-2616, IAF 94-3 182, 
IAF 94-287 Strains described in Pirzadeh et al. Can. J. Vet 
Res, 62: 170-177 and references contained therein). For this 
invention, PRRSV comprising polynucleotide sequences 
associated with a North American PRRSV isolates are 
PRRSV containing polynucleotide sequences wherein the 
GP5 encoding region encodes a polypeptide that has at least 
85% protein sequence identity to SEQID NO:1. 
“European PRRSV, as used herein, refers to any PRRSV 
comprising polynucleotide sequences associated with a 
North American PRRSV isolates, such as, but not limited to, 
the Lelystad strain (Wissink et al., J. Gen. Virol. 85:3715, 
2004 and references contained therein). For this invention, 
PRRSV comprising polynucleotide sequences associated 
with a European PRRSV isolates are PRRSV containing 
polynucleotide sequences wherein the GP5 encoding region 
encodes a polypeptide that has at least 85% protein sequence 
identity to SEQID NO:15. 
“Percent identity”, as used herein, refers to the number of 
elements (i.e., amino acids or nucleotides) in a sequence that 
are identical within a defined length of two optimally aligned 
DNA, RNA or protein segments. To calculate the “percent 
identity”, the number of identical elements is divided by the 
total number of elements in the defined length of the aligned 
segments and multiplied by 100. When percentage of identity 
is used in reference to proteins it is understood that certain 
amino acid residues may not be identical but are nonetheless 
conservative amino acid substitutions that reflect substitu 
tions of amino acid residues with similar chemical properties (e.g., acidic or basic, hydrophobic, hydrophilic, hydrogen 
bond donor or acceptor residues). Such substitutions may not 
change the functional properties of the molecule. Conse 
quently, the percent identity of protein sequences can be 
increased to account for conservative substitutions. 
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Introduction 
The porcine reproductive and respiratory syndrome virus 
(PRRSV) glycoprotein 5 (GP5) is the most abundant enve 
lope glycoprotein and a major inducer of neutralizing anti 
bodies in vivo. Three putative N-linked glycosylation sites 
(N34, N44, and N51) are located on the GP5 ectodomain, 
where a major neutralization epitope also exists. To determine 
which of these putative glycosylation sites are used in 
PRRSV life cycle and the role of the glycan moieties in 
induction of neutralizing antibodies, we generated a panel of 
GP5 mutants containing single and multiple amino acid Sub 
stitutions at these sites. Transient expression of the wild-type 
(wt) as well as the mutant proteins and Subsequent biochemi 
cal studies revealed that the mature GP5 contains high-man 
nose type Sugar moieties at all three sites. These mutations 
were subsequently incorporated into a full-length cDNA 
clone to recover infectious PRRSV. Our results demonstrate 
that mutations involving N44 residue did not result in infec 
tious progeny production, indicating that N44 is the most 
critical amino acid residue for viral infectivity. Viruses car 
rying mutations at N34, N51, and N34/51 grew to lower titers 
than the wt PRRSV and exhibited reduced cytopathic effect in 
MARC 145 cells. In serum neutralization assays, the mutant 
viruses exhibited enhanced sensitivity to neutralization by wt 
PRRSV-specific antibodies. Furthermore, inoculation of pigs 
with the mutant viruses induced significantly higher levels of 
neutralizing antibodies against the mutant as well as the wt 
PRRSV, thus suggesting that the loss of glycan residues in the 
ectodomain of GP5 enhances both the sensitivity of these 
viruses to in vitro neutralization as well as the immunogenic 
ity of the nearby neutralization epitope. These results should 
have great significance for development of PRRSV vaccines 
of enhanced protective efficacy. 
Neutralizing antibodies are known to be a major correlate 
of protection against PRRSV. We have found that elimination 
of glycosylation sites in PRRSV GP5 protein results in sig 
nificant enhancement of: (1) the ability of the modified 
PRRSV strain to be neutralized by a PRRSV convalescent 
antiserum and (2) the ability of this modified PRRSV strain to 
produce unprecedented levels of PRRSV-neutralizing anti 
bodies when used to inoculate pigs. The application of this 
concept to any live (wt or attenuated) virus used for immu 
nizing against PRRSV infection would have significant 
impact in its usage to confer effective protection against 
PRRSV infection. 
At the current time, there exists three main approaches to 
immunize against PRRSV infections: (1) live attenuated vac 
cines, (2) inactivated vaccines (which are based on wt 
PRRSV grown in vitro and chemically inactivated), and (3) 
use of purposeful infection with virulent wt PRRSV in a 
systematic manner to all animals of the herd. There is a lot of 
discussion and controversy about which of these 3 ways is the 
most effective. Our invention would be beneficial, regardless 
of the approach used for immunization. The genetic alteration 
of a live PRRSV to modify the glycosylation level of its 
proteins can be done in either the attenuated PRRSV vaccine 
strain, or the wt PRRSV strain used to produce an inactivated 
vaccine, or the wt PRRSV strain used for directinoculation of 
the herd by mass infection. 
The porcine reproductive and respiratory syndrome virus 
(PRRSV) belongs to the family Arteriviridae within the order 
Nidovirales that also includes equine arteritis virus (EAV), 
lactate dehydrogenase-elevating virus (LDV), and simian 
hemorrhagic fever virus (SHFV). The viral genome is a lin 
ear, positive stranded RNA molecule of approximately 15.0 
kb in length and possesses a cap structure at the 5'-end and a 
poly(A)tail at the 3'-end. Eight open reading frames (ORF) 
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are encoded in the viral genome. The first two open reading 
frames (ORF1a and ORF1ab) encode viral non-structural (NS) polyproteins that are involved in polyprotein processing 
and genome transcription and replication. The viral structural 
proteins, encoded in ORF2-7, are expressed from six subge 
nomic capped and polyadenylated mRNAS that are synthe 
sized as 3'-coterminal nested set of mRNAs with a common 
leader sequence at the 5' end. The major viral envelope pro 
tein is the glycoprotein 5 (GP5), which is encoded in the 
ORF5 of the viral genome. GP5 is a glycosylated transmem 
brane protein of approximately 25 kDa in size. It has a puta 
tive N-terminal signal peptide and possesses three potential 
N-linked glycosylation sites which are located in a small 
ectodomain comprising the first 40 residues of the mature 
protein. In EAV and LDV, the major envelope glycoprotein 
forms a disulfide-linked heterodimer with the ORF6 gene 
product, the viral matrix (M) protein. Similar interaction 
between PRRSV GP5 and M protein has been observed but 
the mode of interaction has not been defined yet. It has been 
postulated that formation of heterodimers of GP5 and M 
proteins may play a critical role in assembly of infectious 
PRRSV. In addition to its role in virus assembly, GP5 appears 
to be involved in entry of the virus into susceptible host cells. 
GP5 is presumed to interact with the host cell receptor, sia 
loadhesin for entry into porcine alveolar macrophages 
(PAMs), the in vivo target cells for PRRSV. The role of GP5 
in receptor recognition is Supported by the presence of a 
major neutralization epitope in the N-terminal ectodomain, 
thus implying a central role for the GP5 ectodomain in the 
infection process. 
The N-linked glycans of the GP5 ectodomain may be criti 
cal for proper functioning of the protein. The N-linked gly 
cosylation, in general, is important for correct folding, target 
ing, and biological activity of proteins. In many enveloped 
viruses, the envelope proteins are modified by addition of 
Sugar moieties and the N-linked glycosylation of envelope 
protein plays diverse functions of viral glycoproteins such as 
receptor binding, membrane fusion, penetration into cells, 
and virus budding. Recent studies have demonstrated the role 
of N-linked glycosylation of Hantaan virus glycoprotein in 
protein folding and intracellular trafficking as well as in bio 
logical activity and antigenicity of influenza virus hemagglu 
tinin (HA) protein. Furthermore, it has become evident that 
glycosylation of viral envelope proteins is a major mecha 
nism for viral immune evasion and persistence used by sev 
eral different enveloped viruses to escape, block or minimize 
the virus-neutralizing antibody response. Examples of this 
effect have been reported for SIV and HIV-1, HBV, influenza 
and more importantly, in the case of PRRSV, the arterivirus 
LDV. 
Recently the development of reverse genetic systems for 
PRRSV has been reported from several laboratories including 
ours. Evidently, mutational studies with infectious clones 
have led to a better understanding of the mechanisms of 
transcription and replication of the viral genome of arterivi 
ruses. Thus, in order to examine the importance of N-linked 
glycosylation in the biological activity of GP5 of PRRSV in 
generating infectious virus or eliciting neutralizing antibod 
ies in vivo, we have constructed a series of mutant GP5 
proteins in which each of the potential N-linked glycosylation 
sites has been mutated either individually or in various com 
binations. The resulting mutant proteins were examined for 
their glycosylation pattern, role in infectious virus recovery 
and in cross neutralization by antibodies raised, through 
experimental inoculations, against the wt PRRSV or against 
the mutant viruses. Our data show that all three putative 
glycosylation sites are used for glycosylation with high-man 
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nose type glycans and glycosylation of GP5 protein at residue 
44 is critical for recovery of infectious PRRSV. Very impor 
tantly, our data from neutralization and antibody response 
studies indicate that natural infection with PRRSV may 
involve an immune evasion based on glycan shielding mecha 
nisms as was previously described for other viruses, thus 
helping to explain the rather ineffective protective humoral 
immune response that is observed in PRRSV-infected ani 
mals. 
N-Linked Glycosylation Sites and Methods of Inactivation 
N-linked glycosylation in glycoproteins typically occurs at 
Asn-Xaa-Ser/Thr (NXS/T) sequences, where Xaa (X) is any 
amino acid residue except Pro. A variety of mutations can be 
introduced at N-linked glycosylation sites to provide for their 
inactivation. A preferred method of inactivation comprises 
Substitution of the asparagine residue with a residue encoding 
any amino acid other than asparagine. In more preferred 
embodiments of this invention, the asparagine residue is Sub 
stituted with an alanine or a glutamine residue. 
Other methods of inactivating N-linked glycosylation 
sites, and in particular the N-linked glycosylation sites cor 
responding to asparagines 34 and/or 51 of the GP5 reference 
protein of SEQID NO:1, are also contemplated herein. Sub 
stitutions of certain amino acids such as proline, tryptophan, 
aspartate, glutamate or Leucine at the Xaa position can also 
be used to inactivate N-linked glycosylation sites (Kasturi et 
al., Biochem J.323 (2):415-9, 1997). Alternatively, substitu 
tions of the final hydroxy amino acid position of the N-linked 
glycosylation site (i.e., the serine or threonine residue of the 
NXS/T sequence) with any non-hydroxy amino acid (i.e., any 
amino acid other than serine or threonine) can also be used to 
inactivate the N-linked glycosylation site. Examples of non 
hydroxy amino acids that have been used to inactivate 
N-linked glycosylation sites include cysteine (Kasturietal., J. 
Biol. Chemistry 270(24), 14756-14761, 1995). 
In addition to amino acid Substitutions, other types of 
mutations that inactivate N-linked glycosylation sites such as 
amino acid insertions or amino acid deletions are also con 
templated by this invention. Those skilled in the art will 
appreciate that an N-linked glycosylation site can be readily 
inactivated by deletions that remove key amino acids in the 
NXS/T sequence (i.e., the asparagine residues) will result in 
the inactivation of that glycosylation site. Deletions of the X 
residue or serine/threonine residue can similarly inactivate 
certain N-linked glycosylation sites where the S or T residue 
is not followed by another S or T residue in the naturally 
occurring sequence. When X is a non-hydroxy amino acid 
(i.e., is not serine or threonine), insertions of any amino acid 
residue at the carboxy terminal end of the N residue can 
inactivate the N-linked glycosylation site. Insertions of any 
non-hydroxy amino acids at the carboxy terminal end of theX 
residue can also inactivate the N-linked glycosylation site. 
In summary, it is understood that the key feature of the 
mutation used to practice the invention is that it inactivates 
N-linked glycosylation at the asparagine 34 and/or aspar 
agine 51 sites in a GP5 protein. While not being limited by 
theory, it is believed that the key feature of these mutations are 
that they prevent glycosylation in a certain region of the 
protein (i.e., residues corresponding to the asparagine 34 
and/or asparagine 51 sites in a GP5 reference protein of SEQ 
ID NO:1). By preventing glycosylation at these sites, Sugar 
residues that ordinarily shield key epitopes of the wild type 
virus are removed, thus permitting elicitation of an improved 
immune response. Consequently, it is anticipated that a num 
ber of different types of mutations (i.e., amino acid substitu 
tion, insertion or deletion) can be used to inactivate the iden 
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tified N-linked glycosylation sites and obtain an antigen that 
will elicit the improved immune response. 
Description of PRRSV Polynucleotides and Polypeptides of 
the Invention 
The methods of this invention can be practiced with a 
variety of different polynucleotides that can be derived from 
a variety of different sources. The common feature of all of 
the polynucleotides is that they encode a hypoglycosylated 
PRRSV GP5 polypeptide variant where N-linked glycosyla 
tion sites corresponding to either asparagine 34, asparagine 
51, or both asparagine 34 and asparagine 54 in a reference 
GP5 protein of SEQID NO:1 are inactivated. To identify the 
N-linked glycosylation sites corresponding to asparagine 34 
and asparagine 54 in the reference GP5 protein of SEQ ID 
NO:1, the non-variant and normally glycosylated PRRSV 
GP5 polypeptide sequence can be aligned with the reference 
GP5 protein of SEQID NO:1. Examples of such an alignment 
are displayed in FIGS. 5 and 6. The particular sequences used 
in this alignment are described in Table 1. 
TABLE 1. 
Description of Sequences 
GenBank Accession 
Description (Reference) Sequence ID NO: 
GPS Protein AAS59265.1 SEQ ID NO: 1 
North American PRRSV strain (Truong, H. M., et 
NVSL 97-7895 al. Virology 325 
(2), 308-319, 
2004) 
GPS Protein AAC412O6. SEQ ID NO: 2 
North American PRRSV strain 
1. IAF-Klop 
GPS Protein 
GPS Protein AAC41209. SEQ ID NO:3 
North American PRRSV strain 
IAF-BA 
GPS Protein AAC41212. SEQ ID NO:4 
North American PRRSV strain 
IAF-DESR 
GPS Protein AAC41215. SEQ ID NO:5: 
North American PRRSV strain 
IAF 93-653 
GPS Protein AAC41218. SEQ ID NO: 6 
North American PRRSV strain 
IAF 93-2616 
GPS Protein AAC41221. SEQ ID NO: 7 
North American PRRSV strain 
94-31.82 
GPS Protein AAC41224. SEQ ID NO: 8 
North American PRRSV strain 
94-287 
GPS Protein AAC28399.1 (with SEQ ID NO: 9: 
North American PRRSV strain Ser 106 as per 
IAF-CM Pirzadeh, B., et 
al. Can. J. Vet. 
Res.62 (3), 170-177 
(1998) 
GPS Protein AAC41227. SEQ ID NO: 10 
North American PRRSV strain 
ONTTS 
GPS Protein AAD12129. SEQ ID NO: 11 
North American PRRSV strain 
VR-2332 
GPS Protein AAA67155. SEQ ID NO: 12: 
North American PRRSV strain 
VR-238S 
GPS Protein AAD27656. SEQ ID NO: 13 
North American PRRSV strain 
MLV 
GPS Protein Pirzadeh, B., et SEQ ID NO: 14 
North American PRRSV strain all. Can. J. Vet. 
Consensus Res.62 (3), 170-177 
(1998) 
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TABLE 1-continued 
Description of Sequences 
GenBank Accession 
Description (Reference) Sequence ID NO: 
GPS Protein AAA47105.1 SEQ ID NO: 15 
European PRRSV strain 
LV 
PRRSV Infectious clone DNA. AAS59265. SEQ ID NO: 16 
North American PRRSV strain (Truong, H. M., et 
NVSL 97-7895 al. Virology 325 
(2), 308-319, 
2004) 
PRRSV Infectious clone DNA AY150564. SEQ ID NO: 17 
North American PRRSV strain (Nielsen, H. S., et 
VR-2332 al., J. Virol. 77 
(6), 3702-3711, 
2003) 
To identify N-linked glycosylation sites corresponding to 
asparagine 34 or asparagine 51 in a reference GP5 protein of 
SEQID NO: 1 that can be inactivated and used in the methods 
of this invention, the GP5 proteins of either a desired North 
American PRRSV isolate (FIG. 5) or a European PRRSV 
isolate (FIG. 6) are aligned with reference GP5 protein of 
SEQID NO: 1 (North American strain NVSL 97-7895). By 
using the GP5 protein of SEQID NO:1 as a reference protein, 
one skilled in the art can readily identify the N-linked glyco 
sylation sites in any GP5 protein and then construct the 
hypoglygosylated GP5 protein variants of this invention. It is 
thus apparent that the term “corresponding to (asparagine 34 
and/or asparagine 51) in a reference GP5 protein of SEQID 
NO:1 serves as a descriptor of the N-linked glycosylation 
site in any GP5 protein. 
The hypoglycosylated GP5 protein can be obtained from a 
North American PRRSV isolate including, but not limited to, 
SEQID NO:1-13, a North American PRRSV isolate that is at 
least 85% identical at an amino sequence level to a North 
American PRRSV consensus sequence such as SEQ ID 
NO:14, or from a North American PRRSV consensus 
sequence. The hypoglycosylated GP5 protein can also be 
obtained from European PRRSV isolates including, but not 
limited to, SEQID NO:15, a European PRRSV isolate that is 
at least 85% identical at an amino sequence level to a Euro 
pean PRRSV consensus sequence such as SEQID NO:15, or 
from a European PRRSV consensus sequence. To obtain the 
hypoglycosylated GP5 variant encoding polynucleotides, 
polynucleotides from any of the sources listed above can be 
mutagenized by standard site-directed mutagenesis tech 
niques such that they will encode a hypoglycosylated GP5 
variant polypeptide. Alternatively, an entirely synthetic DNA 
sequence can be constructed that encodes the desired 
hypoglycosylated GP5 variant polypeptide. This is typically 
accomplished by using a sequence analysis program Such as 
“back translate' which converts a polypeptide sequence into 
a corresponding polynucleotide sequence (GCG Wisconsin 
PackageTM, Accelrys, Inc, San Diego, Calif.). If desired, a 
suitable “codon bias’ can be incorporated into the “back 
translate” program to provide for the design of a synthetic 
gene that incorporates codons appropriate for use in the 
desired expression host (i.e., mammalian or yeast). 
The N-linked glycosylation site corresponding to aspar 
agine 51 of the reference GP5 protein of SEQ ID NO:1 is 
present in all of the representative North American PRRSV 
isolates shown in FIG. 5 and in the representative European 
PRRSV Lelystad strain (FIG. 6). In these exemplary and 
non-limiting North American and European PRRSV strains, 
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the N-linked glycosylation site at this position comprises the 
sequence “NGT. However, it is also anticipated that other 
PRRSV variants may comprise other structurally inter 
changeable N-linked glycosylation sites at this position (i.e., 
NXS or T) that could also be inactivated via the methods 
taught herein. This N-linked glycosylation site can be inacti 
vated by Substituting codons encoding otheramino acid resi 
dues such as glutamine or alanine for asparagine 51 in the 
corresponding polynucleotide sequence. In these instances, 
the corresponding amino acid sequence in the hypoglycosy 
lated North American PRRSV GP5 protein variant would 
comprise the sequences such as “QGT', 'AGT', or “XGT. 
where X is any amino acid other than asparagine. These or 
other hypoglycosylated variants of the North American 
PRRSV GP5 protein isolates where the N-linked glycosyla 
tion site corresponding to asparagine 51 is inactivated can 
also be combined with other hypoglycosylated GP5 variants 
where other N-linked glycosylation sites are inactivated. 
Other methods of inactivating N-linked glycosylation sites 
includeamino acid substitutions of the “X” or "S/T residues 
of the NXS/T sequence, amino acid deletions or amino acid 
insertions and are described above. 
The N-linked glycosylation site corresponding exactly to 
asparagine 34 of the reference GP5 protein of SEQID NO:1 
is present in only certain representative North American 
PRRSV isolates shown here (FIG. 5). More specifically, the 
GP5 proteins of North representative American PRRSV iso 
lates IAF-BAJ (SEQID NO:3), 94-3182 (SEQID NO:7), and 
94-287 (SEQ ID NO:8) contain the N-linked glycosylation 
site corresponding exactly to asparagine 34 of the reference 
GP5 protein of SEQ ID NO:1 and comprises the N-linked 
glycosylation site “NSS”. It is of course anticipated that other 
PRRSV GP5 isolates not shown here will also contain 
N-linked glycosylation sites corresponding to asparagine 34 
of the reference GP5 protein of SEQ ID NO:1 and that 
hypoglycosylated variants of these other GP5 proteins can 
also be obtained using the methods described herein. This 
N-linked glycosylation site of SEQID NO:3, 7, and 8 or other 
PRRSV isolates containing the asparagine 34 N-linked gly 
cosylation site can be inactivated by Substituting codons 
encoding other amino acid residues such as glutamine or 
alanine for asparagine 34 in the corresponding polynucle 
otide sequence. In these instances where the N-linked glyco 
sylation site at asparagine 34 is “NSS, the corresponding 
amino acid sequence in the hypoglycosylated North Ameri 
can PRRSV GP5 protein variant would comprise the 
sequences such as “QSS”, “ASS, or “XSS', where X is any 
amino acid other than asparagine. Alternatively, the serine 
residue of the “NSS' sequence can be substituted with a 
non-hydroxy amino acid (i.e., non-serine of non-threonine). 
In these instances, the corresponding amino acid sequence in 
the hypoglycosylated North American PRRSV GP5 protein 
variant would comprise the sequence “NSX', where X is any 
amino acid other than asparagine. An insertion of a non 
hydroxy amino acid between the two serine residues of the 
“NSS' sequence (i.e., between serines 35 and 36) can also be 
used to inactivate this particular glycosylation site. 
In other North American PRRSV isolates that lack the 
N-linked glycosylation site corresponding exactly to aspar 
agine 34 of the reference GP5 protein of SEQID NO:1, other 
N-linked glycosylation sites located at residue 30 (FIG. 5 
“NAS” in SEQID NO:2, 3, 4, 6, 7, 8, 9, 11, 13), and residue 
33 (FIG. 5 “NNS” in SEQID NO:3, 8: “NSS” in SEQ ID 
NO:6, 10, “NDS” in SEQID NO:11, 13) can also be inacti 
vated. In other words, N-linked glycosylation sites in other 
North American isolates located at amino acid positions cor 
responding to residues 30 and 33 of the reference GP5 protein 
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of SEQ ID NO:1 can also be inactivated and used in the 
methods of this invention. Without being limited by theory, 
the particular region of the PRRSV GP5 protein located 
between residues 29 and 35 of the GP5 reference protein of 
SEQID NO:1 appears to be a hypervariable region (FIG. 5) 
that can tolerate a variety of distinct amino sequences (FIG.5; 
also see Pirzadeh et al., Can. J. Vet Res., 1998, 62: 170-177). 
Although certain naturally occurring PRRSV isolates contain 
no N-linked glycosylation sites in this region (i.e., North 
American isolates of SEQID NO:5, 12: European isolate of 
SEQ ID NO:15), other isolates can contain between 1 to 3 
glycosylation sites in this region. Consequently, inactivation 
of any one of the glycosylation sites of a given GP5 protein in 
the region located between residues 29 and 35 of the GP5 
reference protein of SEQID NO:1 is contemplated herein as 
a composition or method for eliciting an improved immune 
response to the PRRSV GP5 protein. Furthermore, inactiva 
tion of more than one or all of the glycosylation sites a given 
GP5 protein in the region located between residues 29 and 35 
of the GP5 reference protein of SEQID NO:1 is also contem 
plated herein as a composition or method for eliciting an 
improved immune response to the PRRSV GP5 protein. 
Alignment of the North American and the European 
PRRSV sequence shows that the N-linked glycosylation site 
corresponding to asparagine 51 of the reference GP5 protein 
of SEQID NO:1 is also present in a representative European 
PRRSV isolate. In this particular instance, the N-linked gly 
cosylation site comprises the sequence “NGT and the aspar 
agine 51 of the SEQID NO:1 reference sequence corresponds 
to asparagine 53 of SEQID NO:15. This N-linked glycosy 
lation site can be inactivated by Substituting codons encoding 
other amino acid residues such as glutamine or alanine for 
asparagine 53 in the corresponding European PRSSV poly 
nucleotide sequence. In these instances, the corresponding 
amino acid sequence in the hypoglycosylated European 
PRRSV GP5 protein variant would comprise the sequences 
such as “QGT”, “AGT', or “XGT, where X is any amino 
acid other than asparagine. These or other hypoglycosylated 
variants of the European PRRSV isolates where N-linked 
glycosylation site corresponding to asparagine 51 is inacti 
vated can also be combined with other hypoglycosylated GP5 
variants where other N-linked glycosylation sites are inacti 
vated. 
The hypoglycosylated GP5 variant proteins can be 
encoded by PRRS viruses that can be used to prepare live, 
killed, or attenuated vaccines for protecting pigs from 
PRRSV infections. In preferred embodiments of the inven 
tion, the hypoglycosylated GP5 variant proteins of this inven 
tion are engineered into infectious PRRSV clones that are 
capable of producing infectious PRRSV RNA. Descriptions 
of infectious North American PRRSV clones that could be 
engineered to encode hypoglycosylated GP5 variant proteins 
are found in U.S. Pat. No. 6,500,662, Nielsen et al., J. Virol. 
77:3702-11, 2003, and Truong et al., Virology 325:308-19, 
2004. North American PRRSV infectious clone sequences 
that can be mutagenized to obtain PRRSV viruses for use in 
vaccines include but are not limited to the North American 
strains NVSL 97-7895 (SEQID NO:16) and strain VR-2332 (SEQ ID NO:17). Descriptions of infectious European 
PRRSV clones that could be engineered to encode hypogly 
cosylated GP5 variant proteins are found in U.S. Pat. No. 
6.268,199. In embodiments where the vaccine comprises a 
live or attenuated PRRSV, the N-linked glycosylation site 
corresponding to N44 in the reference GP5 protein of SEQID 
NO:1 (i.e., the “NLT sequence in FIGS. 5 and 6) is not 
inactivated as glycosylation of this site is required for infec 
tivity of the PRRSV. In the case of the European PRRSV 
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isolates, the N-linked glycosylation site corresponding to 
N44 in the reference GP5 protein of SEQID NO:1 is the NLT 
sequence that begins at asparagine 46 of the representative 
European PRRSV strain Lelystad (SEQ ID NO:15: FIG. 6). 
The N46N-linked glycosylation site of the European PRRSV 
strains is also required for infectivity and is not inactivated in 
embodiments of the invention where a live or attenuated 
PRRSV vaccine is used. 
Alternatively, the hypoglycosylated GP5 variant proteins 
can be introduced into pigs with DNA vaccines. Such DNA 
vaccines typically comprise a DNA molecule wherein a pro 
moter active in mammalian cells is operably linked to said 
polynucleotide encoding said hypoglycosylated PRRSV GP5 
polypeptide variant. Promoters that can be used to drive 
expression of the hypoglycosylated GP5 variant proteins 
include, but are not limited to, the CMV (cytomegalovirus) 
immediate early promoter, RSV (Rous sarcoma virus) long 
terminal repeat promoter, and SV40 (Simian Virus 40) T-an 
tigen promoter. In certain preferred embodiments, this pro 
moter is a CMV promoter. 
In still other embodiments, the isolated polynucleotide 
expressing the hypoglycosylated GP5 variant protein com 
prises a viral vector other than PRRSV. Viral vectors other 
than PRRSV include, but are not limited to, vaccinia virus 
vectors, a herpes simplex viral vectors, adenovirus vectors, 
alphavirus vectors, and TGEV vectors. Such vectors are 
described in various publications such as U.S. Pat. No. 7,041, 
300 (for TGEV vectors) and U.S. Pat. No. 6,692,750 (for 
alphavirus vectors). 
Therapeutically Acceptable Carriers and Adjuvants 
In practicing the invention, the hypoglycosylated GP5 vari 
ant polypeptides or polynucleotides that encode hypoglyco 
sylated GP5 variant polypeptides can be combined with 
therapeutically acceptable carriers or excipients. Non limit 
ing examples of such carriers include physiological saline or 
other similar saline Solutions, proteins such as serum albumin 
proteins, buffers such as carbonate, phosphate, phosphonate, 
or Tris based buffers, surfactants such as NP40 or Triton 
X100, and a polyethylene glycol polymers. Any combination 
of such carriers can be used in the compositions and methods 
of this invention. A preferred carrier for compositions com 
prising live or attenuated PRRSV viruses is dl-C-tocopherol 
acetate at a concentration of between 50 to 100 mg/ml. 
The use of adjuvants in compositions containing either the 
hypoglycosylated GP5 variant polypeptides or polynucle 
otides that encode hypoglycosylated GP5 variant polypep 
tides is also contemplated. Such adjuvants are typically either 
aqueous or oily in nature. Adjuvants that can be used include, 
but are not limited to, aluminum hydroxide, Quil A, an alu 
mina gel Suspension, mineral oils, glycerides, fatty acids, 
fatty acid by-products, mycobacteria, and CpG oligodeoxy 
nucleotides, or any combination thereof. Various types of 
CpG adjuvants that can be used are described U.S. Pat. Nos. 
6,977,245 and 6,406,705. 
The use of other adjuvants that potentiate cellular immune 
responses (i.e., T helper cell (Th..sub.1 and Th. Sub.2) Sub 
population potentiators) is also contemplated. Such adjuvants 
include but are not limited to interleukin 1 (IL-1). IL-2, IL4. 
IL-5, IL6, IL-12, gamma interferon (g-IFN), cell necrosis 
factor, MDP (muramyl dipeptide), immuno stimulant com 
plex (ISCOM), and liposomes. 
Administration of the composition can be accomplished by 
Subcutaneous injection, intravenous injection, intradermal 
injection, parenteral injection, intramuscular injection, 
needle free injection, electroporation, oral delivery, intranasal 
delivery, oronasal delivery, or any combination thereof. 
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Needle free injection is typically effected with a device such 
as an Agro-JetR) injector (Medical International Technolo 
gies, Montreal, Canada). 
EXAMPLES 
Example 1 
The following example illustrates the construction of vari 
ous PRRSV polynucleotides that encode various hypoglyco 
sylated North American PRRSV GP5 polypeptide variants, 
compositions including Such polynucleotides that are used to 
elicit improved immune responses to a PRRSV antigen, and 
methods of using the polynucleotides and compositions to 
elicit an improved immune response in a pig to a PRRSV 
antigen. 
Materials and Methods 
Cells, media, and antibodies. The MARC-145 cells were 
propagated in Dulbecco's Modified Eagle's Medium 
(DMEM) containing 10% fetal bovine serum (FBS) and 100 
units of penicillin, 20 units of streptomycin and 20 units of 
kanamycin per ml of growth medium. These cells were used 
for RNA electroporation, virus infection, viral growth, and 
plaque assays. The baby hamster kidney (BHK-21) cells were 
maintained in Minimal Essential Medium (MEM) with Earl's 
salt containing 5% FBS and the above mentioned antibiotics. 
BHK-21 cells were used for transient expression of GP5 
followed by either immunofluorescence assays (IFA) or 
radiolabeling and immunoprecipitation experiments. All 
cells were maintained at 37° C. and 5% CO2 environment. 
Rabbit polyclonal antibodies to PRRSV GP5 and M proteins 
were kindly provided by Carl A. Gagnon (University of Que 
bec, Montreal, Canada). The monoclonal antibody 
(SDOW17) against nucleocapsid protein (N) was purchased 
from National Veterinary Services Laboratories (NVSL, 
Ames, Iowa, USA). Anti-mouse Alexa-488 was obtained 
from Molecular Probes, Inc. (Eugene, Oreg., USA). 
Genetic Manipulation of Plasmids Encoding GP5 and 
PRRSV Infectious Clone 
The full-length PRRSV infectious cDNA clone (FL12: 
SEQ ID NO:16) in pBR322 was digested with EcoRV and 
Bst717 I restriction enzyme and the -4.9 kbp fragment 
encompassing majority of ORF2, complete ORF3-7, and the 
entire 3'UTR of PRRSV was cloned in pBR322 using the 
same enzyme sites. This intermediate plasmid served as the 
template for mutagenesis to introduce mutations at the poten 
tial N-linked glycosylation sites (N34, N44, and N51) within 
GP5 (FIG. 2). Mutagenesis was carried out using overlap 
extension PCR with synthetic primers (Table 2) using stan 
dard techniques. 
TABLE 2 
Primers and their sequences used in this study. 
Primers Nucleotide sequences 
GP5-N34A-For 5 GCCAACAGCGCCAGCAGCTCTC 3' 
(SEQ ID NO:18) 
GP5-N44A-For s' GTTGATTTACGCCTTGACGCTATG 3." 
(SEQ ID NO:19) 
GP5-N51A-For 5 GTGAGCTGGCTGGCACAGATTG 3." 
(SEQ ID NO: 2O) 
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TABLE 2 - continued 
Primers and their sequences used in this study. 
Primers Nucleotide sequences 
GP5-N3.4/44A-For s' GCCAACAGCGCCAGCAGCTCTCATCTTCA 
GTTGATTTACGCCTTGACGCTATG 3." 
(SEQ ID NO:21) 
GP5-N44/51A-For s' GTTGATTTACGCCTTGACGCTATGTGAGC 
TGGCTGGCACAGATTG 3." 
(SEQ ID NO: 22) 
GP5-N3.4/51A-For s' GCCAACAGCGCCAGCAGCTCTCATCTTCA 
GTTGATTTACAACTTGACGCTATGTGAGCTGG 
CTGGCACAGATTG 3' 
(SEQ ID NO:23) 
GP5-N34/44/51A-For 5' GCCAACAGCGCCAGCAGCTCTCATCTTCA 
GTTGATTTACGCCTTGACGCTATGTGAGCTGG 
CTGGCACAGATTG 3' 
(SEQ ID NO:24) 
PRRSW-13177 - For 5' CTACCAACATCAGGTCGATGGCGG 3." 
(SEQ ID NO:25) 
PRRSW-14473 - Rew s' GTCGGCCGCGACTTACCTTTAGAG 3 '' 
(SEQ ID NO: 26) 
Underlined codon sequences indicate the site of 
mutation. 
The PCR product was digested with BsrG I and BstE II 
restriction enzymes and replaced back in the intermediate 
plasmid. Clones containing the desired mutations were iden 
tified and confirmed by sequencing. The entire coding region 
of GP5 was sequenced to make sure that additional mutations 
were not present in the clones. The EcoRV-Pac I fragment 
from the intermediate plasmid containing mutations in the 
GP5 coding region was moved back into the full-length 
cDNA clone using the same restriction enzyme sites. The 
GP5 coding region in the full length clones was again 
sequenced with PRRSV specific internal primers to confirm 
the presence of the mutations. 
The wt GP5 and individual mutants were cloned in a bicis 
tronic vector where the GP5 is the first cistron followed by 
encephalomyocarditis virus (EMCV) internal ribosome entry 
site (IRES) and M coding sequences (FIG. 1A). The full 
length GP5 was also cloned in a CMV promoter driven vector 
(pcDNA 3.0TM, Clontech Laboratories, Inc., Mountain View, 
Calif., USA) for complementation studies. To this end, the 
GP5 coding region was PCR amplified, cloned and 
sequenced. 
In Vitro Transcription and Electroporation 
The full-length plasmids were digested with AclI and lin 
earized DNA was used as the template to generate capped 
RNA transcripts using the mMESSAGE mMACHINE Ultra 
T7TM kit as per manufacturers (Ambion, Inc., Austin, Tex., 
USA) recommendations and as described earlier. The reac 
tion mixture was treated with DNasel to digest the DNA 
template and extracted with phenol and chloroform and 
finally precipitated with isopropanol. The integrity of the in 
vitro transcripts was analyzed by glyoxal agarose gel electro 
phoresis followed by ethidium bromide staining. 
MARC-145 cells were electroporated with approximately 
5.0 g of in vitro transcripts along with 5.0 ug of total RNA 
isolated from MARC-145 cells. About 2x 106 cells in 400 ul 
of DMEM containing 1.25% DMSO were pulsed once using 
Bio-Rad Gene Pulser XcellTM (Bio-Rad, Inc., Hercules, 
Calif., USA) at 250V,950 uF in a 4.0 mm cuvette. The cells 
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were diluted in normal growth media, plated in a 60-mm cell 
culture plate. A small portion of the electroporated cells was 
plated in a 24-well plate to examine expression of N protein at 
48 hrs post-electroporation, which would indicate genome 
replication and transcription. Once expression of N protein is 
confirmed using indirect immunofluorescence assay (IFA), 
the supernatant from bulk of the electroporated cells in 
60-mm plate was collected at 48 hrs post-electroporation, 
clarified and passed onto naive MARC-145 cells. The 
infected cells were observed for cytopathic effect (CPE) 
along with the expression of N protein using IFA. The super 
natants from infected cells showing both CPE and positive 
fluorescence were assigned to contain infectious virus. After 
confirmation, the virus stock was grown and frozen at -80°C. 
in Small aliquots for further studies. In all the experiments, 
FL12 containing wt PRRSV genome and FL12pol-contain 
ing polymerase-defective PRRSV genome were used as con 
trols. 
Metabolic Radiolabeling and Analyses of Proteins 
BHK-21 cells in six-well plates were infected with recom 
binant vaccinia virus (VTF7-3) at an MOI of 3.0 and subse 
quently transfected with bicistronic plasmid DNA encoding 
wt or various mutant GP5 under T7 RNA polymerase pro 
moter. DNA transfection was carried out using Lipo 
fectamine2000TM as per manufacturer's protocol (Life Tech 
nologies, USA). At 16 hrs post-transfection, cells were 
washed twice with PBS and starved in methionine/cysteine 
free DMEM for one hr and radiolabeled with 0.6 ml of 
methionine/cysteine-free DMEM containing 100 uCi of 
ExpreSS Protein Labeling Mix (NEN Life Sciences, Bos 
ton, Mass.) per ml of medium for three hrs. Following radio 
labeling, the cells were washed in cold PBS three times and 
cell extracts were prepared in 300 ul of radioimmunoprecipi 
tation assay (RIPA) buffer (10 mM Tris-HCl pH 8.0, 150 mM 
NaCl, 1% Triton X-100, 0.1% SDS, 1% Sodium deoxycho 
late, and 1x protease inhibitor). The clarified cell extracts 
were incubated overnight at 40 C with rabbit anti-GP5 or 
anti-M protein antibody. A slurry of approximately 4.0 mg of 
protein Asepharose (Pharmacia, Uppsala, Sweden) in 100 ul 
RIPA buffer was added and further incubated for 2 hrs. The 
immunoprecipitated complexes were washed 3 times with 
500 ul of RIPA buffer and used for further analysis. 
For endoglycosidase H (Endo H) treatment, the immuno 
precipitated complexes were resuspended in 20ll of 1x dena 
turing buffer (0.5% SDS, 1.0% f-mercaptoethanol) and 
boiled for 10 min. The supernatant was collected, adjusted to 
1x G5 buffer (0.05 M sodium citrate pH 5.5) and incubated 
for 16 hrs at 37°C. with 100 units of Endo H (New England 
Biolabs, Beverly, Mass., USA). The undigested control 
samples were processed similarly but no Endo H was added. 
Following Endo H digestion, the samples were mixed with 
equal volume of 2xSDS-PAGE sample buffer, boiled for 5 
min and resolved by SDS-12% PAGE under denaturing con 
ditions along with protein marker (Protein Plus Precision 
Standard, Bio-Rad, Inc). The gel was fixed with 10% acetic 
acid for 15 min, washed three times with water, treated with 
0.5M sodium salicylate for 30 min, dried and finally exposed 
to X-ray film at -70° C. For peptide N-Glycosidase F (PN 
Gase F) (New England Biolabs, Inc) digestion, immunopre 
cipitated complexes were resuspended in 1x G7 buffer (0.05 
M sodium phosphate pH 7.5, 1.0% NP-40) and digestion was 
performed by incubating for 16 hrs at 37°C. with 2 units of 
the enzyme. To examine synthesis of GP5 in the presence of 
tunicamycin (Sigma, St. Louis, Mo.), transfected cells were 
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treated with 2.0 ug of tunicamycin per ml of medium for one 
hr and radiolabeling was performed in the presence of the 
drug for 3 hrs as above. 
For obtaining radiolabeled extracellular virions or intrac 
ellular virus expressed GP5, MARC-145 cells were infected 
with wt or mutant PRRSVs. At 48 hrs post-infection, the cells 
were starved for one hr and radiolabeled with 100 uCi of 
Express Protein Labeling Mix per ml of medium con 
taining 90% methionine/cysteine free DMEM and 10% regu 
lar DMEM for 24 hrs. Following labeling, the culture super 
natant was harvested, cleared of cell debris and the 
extracellular virions were pelleted at 100,000xg for 3 hrs at 4 
C. The viral pellets were resuspended in 200 ul of RIPA 
buffer, immunoprecipitated with anti-GP5 antibody and the 
proteins were examined with or without Endo H treatment. 
For immunoprecipitation of intracellular virus expressed 
GP5, infection was carried as above and at 24 hrs post-infec 
tion, the cells were starved for one hr, radiolabeled as above 
for 2 hrs prior to preparing cell extracts. 
Viral Growth Kinetics and Plaque Assay 
MARC-145 cells were infected with mutant or wt PRRSV 
at an MOI of 3.0 PFU per cell and incubated at 370 C in an 
incubator. At various time points post-infection, aliquots of 
culture supernatants from infected cells were collected and 
virus titer in the Supernatants was determined and expressed 
by tissue culture infectious dose 50 per ml (TCID50/ml). The 
viral growth kinetics was performed three times. To examine 
the plaque morphology of mutant viruses, plaque assay was 
performed using MARC-145 cells. Cells were infected with 
10-fold serial dilutions of individual viruses for one hr at 37° 
C. The infected cell monolayer was washed with PBS and 
overlaid with DMEM-5% FBS containing 0.8% Seaplaque 
agarose (FMC Bioproducts, Rockland, Me. USA). After 96 
hrs, the agarose plugs were removed and cell monolayer was 
incubated with staining solution (20% Formaldehyde 9.0% 
Ethanol, and 0.1% Crystal violet) for 30 min at room tem 
perature. The cells were gently washed with water to remove 
excess dye and air dried to examine and count the plaques. 
Complementation of Virus Recovery by Expressing Wt GP5 
in Trans 
BHK-21 cells were transfected with pcDNA-GP5. At 40 
hrs post-transfection, the cells were harvested and electropo 
rated with capped in vitro transcripts derived from full-length 
PRRSV cDNA encoding mutant GP5. The electroporated 
cells were diluted with fresh media and plated in 6-well plate. 
The supernatant from electroporated cells was collected at 48 
hrs post-electroporation, centrifuged to remove cell debris 
and used to infect naive MARC-145 cells. The infected 
MARC-145 cells were examined at 48 hrs post-infection for 
expression of N protein by IFA as described above. The 
number of positive cells was counted to assign the number of 
pseudo-particles produced in the Supernatant. The average 
number of positive cells was calculated from three indepen 
dent experiments and was presented as the number of pseudo 
particles produced per microgram of invitro transcribed RNA 
transfected into the cells. 
Serum-Neutralization (SN) Assays 
The titer of PRRSV-neutralizing antibodies in a serum 
sample was determined using the fluorescence focus neutral 
ization assay described previously. Serial dilutions oftest sera 
were incubated for 60 min at 37° C. in the presence of 200 
TCID50 of the challenge virus, which consisted of either 
FL12 (wt PRRSV) or any of the GP5 mutant encoding 
viruses, FL-N34A, FL-N51A, and FL-N34/51A in Dulbec 
co's modified Eagle's medium containing 5% fetal calf 
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serum. The mixtures were added to 96-well microtitration 
plates containing confluent MARC-145 cells which had been 
seeded 48 hrs earlier. After incubation for 24 hrs at 37°C. in 
a humidified atmosphere containing 5% CO2, the cells were 
fixed for 10 min with a solution of 50% methanol and 50% 
acetone. After extensive washing with PBS, the expression of 
N protein of PRRSV was detected with monoclonal antibody 
SDOW17 using a 1:500 dilution, followed by incubation with 
FITC-conjugated goat anti-mouse IgG (Sigma, St. Louis, 
Mo., USA) at a 1:100 dilution. Neutralization titers were 
expressed as the reciprocal of the highest dilution that inhib 
ited 90% of the foci present in the control wells. 
Experimental Inoculation of Pigs with GP5 Mutants and Wt 
PRRSV 
High titer stocks (obtained through 3 passages in MARC 
145 cells) of the GP5 mutant viruses (FL-N34A, FL-N51A, 
and FL-N34/51A) and the FL12 (wt PRRSV) were used to 
infect young pigs. Twenty-one-day old, recently weaned pigs 
were purchased from a specific-pathogen-free herd with a 
certified record of absence of PRRSV infection. All animals 
were negative for anti-PRRSV antibodies as tested by ELISA 
(Iddex Labs, Portland, Me...). Three pigs per group were 
infected with either FL12 wt PRRSV or mutants FL-N34A, 
FL-N51A, and FL-N34/51A. In all cases, the inoculum con 
sisted of 105 TICD50 diluted in 2 ml and administered intra 
muscularly in the neck. The rectal temperatures of the inocu 
lated animals were monitored for 15 days post-inoculation 
(PI). Viremia was measured by regular isolation on MARC 
145 cells at days 4, 7 and 14 PI. Serum samples were drawn 
weekly for a total period of 49 days PI. The serum samples 
were used to detect homologous and heterologous cross 
neutralization titers for each of the mutants and wt PRRSV. 
Results 
Expression and Characterization of PRRSV GP5 
The GP5 of PRRSV strain 97-7895 has three putative gly 
cosylation sites (N34, N44, and N51). To examine the glyco 
sylation pattern of GP5, we first generated abicistronic vector 
in which the coding regions of GP5 and M proteins flanking 
the IRES from EMCV were placed under the control of T7 
RNA polymerase promoter (FIG. 1A). The rationale for con 
structing the bicistronic vector is that the GP5 and M proteins 
are known (for LDV and EAV) or postulated (for PRRSV) to 
interact with each other and that Such interactions may be 
important for protein folding, glycosylation, intracellular 
transport, and/or other biological activity of GP5. 
Transient expression of GP5 and M by transfection of the 
bicistronic plasmid followed by radiolabeling and immuno 
precipitation with anti-GP5 antibody revealed two major pro 
tein species. The protein species migrating with a mass of 
-25.5 kDa is the fully glycosylated form of GP5 (FIG. 1B, 
lane 2). Since each N-linked glycosylation adds -2.5 kDa of 
molecular mass to a protein, this indicates that all three poten 
tial glycosylation sites are possibly used for glycosylation of 
GP5. The 19.0kDa protein species is the viral M protein since 
it was also was immunoprecipitated with anti-M antibody 
(lane 7). The results indicate that GP5 and M proteins interact 
with each other in cells expressing both proteins. Upon treat 
ment with Endo H, an enzyme that removes high-mannose 
type oligosaccharide chains, the size of the GP5 was reduced 
to ~18 kDa, whereas the size of the M protein remained 
unchanged (lane 3). Treatment of GP5 with PNGase F (lane 
4), an enzyme that removes all type Sugars from protein 
backbone or synthesis of GP5 in the presence of tunicamycin 
(lane 5) resulted in a protein that migrated with slightly faster 
electrophoretic mobility than the protein with Endo-H treat 
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ment. This is expected, since tunicamycin treatment or diges 
tion with PNGase F would generate unglycosylated proteins 
whereas Endo-H treatment would result in proteins that retain 
N-acetylglucosamine residues at each of the N-linked glyco 
Sylation sites. It is of note that a prominent protein species of 
~30 kDa molecular mass was immunoprecipitated with 
anti-Mantibody. The identity of this protein is not known but 
it could be a cellular protein that interacts with the M protein. 
The results from the above studies suggest that the ungly 
cosylated and fully glycosylated forms of GP5 possess appar 
ent molecular sizes of 18.0 kDa and 25.5 kDa, respectively. It 
appears that all three potential glycosylation sites are used to 
generate the fully glycosylated form of GP5. The glycan 
moieties added to these sites are of high-mannose type since 
they are sensitive to digestion by Endo H. In addition, the 
results indicate that both unglycosylated and fully glycosy 
lated forms of GP5 appear to interact with the M protein. 
Analysis of N-Linked Glycosylation Sites Used for Glycosy 
lation of GP5 
To more precisely determine whether all or some of the 
potential N-linked glycosylation sites in GP5 are used for 
addition of Sugar moieties, a series of mutants were generated 
in the bicistronic plasmid where all three potential glycosy 
lation sites N34, N44, and N51 (FIG. 2A) were altered to 
alanines either individually or in various combinations (FIG. 
2B). In plasmid-transfected cells, the proteins were radiola 
beled and immunoprecipitated with anti-GP5 antibody. The 
immune complexes were either left untreated or treated with 
Endo Hand examined by SDS-PAGE. As can be seen from 
the data presented in FIG. 2C, mutant GP5 proteins carrying 
single mutations (N34A, N44A or N51A) migrated as 
approximately 23.0 kDa protein species (lanes 4, 6 and 8. 
arrowhead). Upon Endo H treatment, these proteins migrated 
as ~18.0 kDa protein species (lanes 5, 7, and 9, respectively) 
similar to the wt GP5 after Endo H treatment (lane 3). The 
minor differences in electrophoretic mobility of the proteins 
is most likely reflective of the fact that the wt protein would 
retain all three N-acetylglucosamine residues following Endo 
H treatment as compared to the single mutants that would 
contain two such residues. The double mutants (N34/44A, 
N44/51A and N34/51A) produced protein species that 
migrated close to -20.5 kDa protein (lanes 10, 12 and 14) and 
upon Endo H treatment, the size of the proteins was reduced 
to 18.0 kDa (lanes 11, 13, and 15). The triple mutant (N34/ 
44/51A) generated a protein that migrated as 18.0kDa protein 
(lane 16) and was resistant to Endo H digestion (lane 17). 
Thus, from the above mutational studies, it is clear that all 
the three potential glycosylation sites are used for glycosyla 
tion to generate fully mature PRRSV GP5. It appears that all 
three glycosylation sites are modified by high-mannose type 
glycan moieties. 
Recovery of Infectious PRRSV Virus with GP5 Mutants 
To assess the importance of N-linked glycosylation ingen 
eration of infectious PRRSV, the coding regions of the mutant 
GP5 proteins were inserted into the full-length cDNA clone. 
Capped in vitro transcripts produced from the clones were 
electroporated into MARC-145 cells and generation of infec 
tious PRRSV was examined. Our results showed that infec 
tious virus was readily recovered from the cells electropo 
rated with full-length transcripts containing mutations at 
N34, N51, and N34/51. However, under similar conditions of 
virus recovery, repeated attempts to recover other mutant 
viruses were unsuccessful. Although the growth kinetics of 
the recovered viruses were similar to that of the wt virus, the 
overall yield of FL-N34A and FL-N51 A viruses containing 
mutations at N34 and N51 was approximately one log less in 
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MARC-145 cells while that of FL-N34/51A with double 
mutations (N34/51A) was almost 1.5 log less than the wt 
PRRSV (FIG. 3A). The RT-PCR amplification of RNA from 
infected cells followed by nucleotide sequencing indicated 
that these viruses are stable, contained the desired mutations 
and no other mutations were detected in the entire GP5 region 
(data not shown). 
Viral plaque assay was performed on MARC-145 cells to 
monitor the plaque phenotype of mutant viruses. The plaques 
generated by wt PRRSV were clear and distinct while the 
mutant viruses produced plaques that have different pheno 
types. FL-N34A, FL-N51A and FL-N34/51 A viruses gener 
ated plaques that were less distinct and many of the cells 
within the plaque appeared normal (FIG. 3B, open arrow). In 
addition, FL-N51A, FL-N34/51 A produced some plaques in 
which the viruses failed to clear the cell monolayer (FIG.3B, 
solid arrow). This data indicate that the recovered mutant 
viruses are indeed less cytopathic as compared to wt PRRSV. 
Since we were unable to recover infectious PRRSV with 
mutant templates FL-N44A, FL-N31/44A, FL-N44/51A, and 
FL-N31/44/51A, it is possible that mutations in GP5 coding 
region may have affected some other functions of the RNA 
templates, such as packaging of the genomic RNA into par 
ticles. To address this, we examined whether cells expressing 
wt GP5 in trans could support packaging of mutant RNA 
templates that are otherwise defective in generating infec 
tious PRRSV. BHK-21 cells transfected with pcDNA-GP5 
were electroporated with in vitro transcripts and at 48 hrs 
post-electroporation, the culture Supernatants were collected 
and used to infect naive MARC-145 cells to determine the 
production of PRRSV pseudo-particles. If the pseudo-par 
ticles are generated, one would then expect to observe expres 
sion of the N protein in these infected MARC-145 cells. The 
expression of N is only possible when naive MARC-145 cells 
receive full-length encapsidated mutant RNA genome that 
sets up replication following entry of the pseudo-particles 
into cells. Of all the mutants that could not be recovered 
previously, we were able to recover pseudo-particles contain 
ing two mutant full-length genomes (FL-N44A and FL-N34/ 
44A) (FIG. 3C). Each green fluorescing cell in the mutant 
virus-infected culture represents one infectious pseudo-par 
ticle. Since these particles contain only the functional wt GP5 
on the envelope but contain the coding sequences for non 
functional mutant GP5 in the genome, they cannot produce 
infectious particles to spread to Surrounding cells. Multiple 
attempts to recover pseudo-infectious particles with the other 
mutant templates (FL-N44/51A, and FL-N31/44/51A) were 
unsuccessful. 
A quantitative estimation of the number of infectious 
pseudo-particles produced from these experiments suggests 
that approximately 1000 particles are produced per micro 
gram of mutant RNA electroporated into the cells (FIG. 3D). 
This is approximately 100 fold less than that obtained with 
RNA encoding wt GP5. Production of such low levels of 
infectious pseudo-particles could be due to the fact that only 
about 5-10% of cells that expressed the wt GP5 received the 
full-length transcripts as seen by the expression of the N 
protein in these cells. It is also possible that low levels of 
expression of wt GP5 in the transfected cells may have con 
tributed to the low levels of production of these pseudo 
virions. 
Examination of GP5 Incorporated into Mutant Viruses and 
Those Expressed in Infected Cells 
To determine the nature of GP5 protein incorporated into 
infectious virions produced from transfected cells, we gener 
ated radiolabeled PRRSV from cells infected with wt and 
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mutant viruses. The extracellular virions present in the cul 
ture supernatant were pelleted by ultracentrifugation and GP5 
present in these virions was examined by immunoprecipita 
tion using anti-GP5 antibody and subsequent electrophoretic 
analysis. Results show the wt GP5 incorporated into virions 
migrated as a broadly diffuse band of ~25-27 kDa protein 
species (FIG. 4A, lane 1), which is partially resistant to Endo 
H digestion (lane 2). Mutant GP5 (N34A and N51A) incor 
porated into virions were sensitive to Endo H. Based on the 
size of the products generated following Endo H digestion, it 
appears that only one glycan moiety in these single site 
mutants is sensitive while the other is resistant. In contrast, 
the double mutant GP5 (N43/52A) was resistant to Endo H. 
Furthermore, Endo H digestion of GP5 from mutant viruses 
also produced very small amounts of GP5 protein backbone, 
indicating that these viruses incorporate GP5 proteins that 
contain Endo H-resistant as well as Endo H-sensitive glycan 
moieties. 
Since in cells transfected with the bicistronic vector, the wt 
as well as the mutant GP proteins were completely Endo H 
sensitive (FIGS. 1 and 2), we were surprised by the observa 
tion that GP5 on PRRS virions contained largely Endo H 
resistant forms. To examine if the Endo H resistant forms of 
the protein are also synthesized in infected cells, MARC-145 
cells infected with wt or mutant PRRSV were radiolabeled, 
GP proteins were immunoprecipitated with anti-GP5 anti 
body and analyzed by electrophoresis with or without Endo H 
digestion. Results of Such an experiment are shown in FIG. 
4B. Majority of wt GP5 contained Endo H-resistant glycans 
at all three sites (lanes 2 and 3), whereas the two single 
mutants contained Endo H-resistant glycans only at one site 
(lanes 4-7). Some of the glycan moieties in the double mutant 
are resistant while others are sensitive to Endo H (lanes 8 and 
9). Although the pattern of Endo H-resistance is similar to 
what is observed for virion-associated GP5, it is different 
from that observed in cells expressing both GP5 and M pro 
teins (FIGS. 1 and 2). These results indicate that other viral 
proteins may play a role in further modification of glycans on 
GP5. Influence of hypoglycosylation of GP5 on PRRSV’s 
ability to be neutralized by specific antibodies. 
The level of glycosylation of viral glycoproteins that are 
involved in the interaction with viral receptors is known to 
affect the ability of virions to react with virus-neutralizing 
antibodies. To test whether this phenomenon occurs in the 
case of PRRSV, the PRRSV GP5 mutants with altered gly 
cosylation patterns (FL-N34A, FL-N51A and FL-N34/51A) 
were compared with PRRSV wt (FL12) in their ability to be 
neutralized by convalescent antisera. For this, we used con 
Valescent antisera (47 days p.i.) from 4 animals that had been 
infected with wt PRRSV. Similar doses (2,000 TCID50) of 
infectious PRRSV GP5 mutants (FL-N34A, FL-N51A and 
FL-N34/51A) as well as of the infectious clone-derived wit 
PRRSV (FL12) were used as challenge virus in serum-neu 
tralization assays following our standard assay protocol and 
the set of 4 anti-wt PRRSV (FL12) sera used as reference. 
Table 3 shows the different end-point serum neutralizing 
titers obtained. Normally, a PRRSV wit-convalescent serum 
sample collected at 47-54 days p.i. contains moderate levels 
of wt PRRSV neutralizing activity (1:8 to 1:32, Tables 3 and 
4), reflecting the relatively weak and tardy character of the 
neutralizing antibody response that is typical of infections 
with wt PRRSV. However, the use of hypoglycosylated 
PRRSV mutants (which lack one or two glycan moieties on 
the GP5 ectodomain) as challenge virus in the SN assays 
seem to have significantly enhanced the end-point of the 
reference Sera, with end-point titer enhancement ranging 
from six to twenty-two fold (Table 3). This observation 
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clearly suggests that the removal of one, and particularly two, 
of the glycan moieties increases the accessibility of the neu 
tralizing epitope to specific antibodies. These results appear 
to indicate the presence of significant amount of PRRSV 
neutralizing antibodies in the wt PRRSV-infected convales 
cent sera that would otherwise be undetectable because of the 
typical use of wt PRRSV containing fully glycosylated GP5 
in SN assays. 
TABLE 3 
Effect of alteration of glycosylation pattern of PRRSV GP5 on the 
ability of the infectious virion to react with neutralizing antibodies. 
Numbers in Table 3 correspond to the inverse end point dilution 
showing neutralization (SN endpoint). 
Serum from animals 
infected with 10 PRRSV strain used as challenge for SN test 
TCIDso of wt PRRSV Wt FL- FL-N34. 
FL12 PRRSV(FL12) N34A FL-N51A 51A 
Animal No. 1:32 1:256 1:256 1:32,768 
11404(47 days pi) 
Animal No. 1:8 1:64 1:256 1:16,384 
11346(47 days pi) 
Anirnal No. 1:16 ND 1:128 1:2,048 
11457(47 days pi) 
Animal No. 1:8 ND 1:64 1:2,048 
11407(47 days pi) 
Influence of Hypoglycosylation of GP5 on PRRSV’s Ability 
to Induce Neutralizing Antibodies In Vivo 
One remarkable effect that has been reported where carbo 
hydrate removal from a viral envelope glycoprotein leads to 
production of high titers of neutralizing antibodies against the 
mutant virus when this mutant is used for in vivo inoculation 
of the host; in some cases also inducing higher titers of anti 
body to the wt virus than the wt virus itself. We infected 
groups of pigs with identical doses of either the wt PRRSV 
FL12 or of each of the mutants with altered glycosylation 
patterns. Interestingly, clinical/virological assessment of the 
infection by evaluation of rectal temperature and evaluation 
of viremia at days 4, 7 and 10 p.i. indicated a similar pattern 
of infection in all groups as previously described for FL12 
without evidence of virulence attenuation or exacerbation for 
either of the mutants (data not shown). However, the sequen 
tial sampling of serum from these animals throughout a 
period of 48 days indicated pronounced differences between 
the wt PRRSV and the mutants in their kinetics of induction 
of a PRRSV-neutralizing antibody response (Tables 4A and 
4B). The mutants developed an early and more robust 
homologous neutralizing antibody response than that devel 
oped by wt PRRSV, to the point where, in the case of the 
mutants, the characteristically sluggish and meager nature of 
PRRSV-neutralizing antibody response appears to have been 
corrected (Table 4B). The kinetics of appearance of mutant 
homologous neutralizing antibodies (Table 4B) indicate a 
more regular neutralizing antibody seroconversion consistent 
with that described for other viral infections such as influenza 
or Pseudorabies virus but not for PRRSV. Of utmost impor 
tance is the fact that the infection with GP5 glycosylation 
mutants induced a wt PRRSV-specific neutralizing antibody 
response that is significantly higher than the response with the 
wt PRRSV itself. The mutant viruses FL-N34 and FL-N51A 
induced five-fold higher (p<0.05) levels of neutralizing anti 
body titer against wt PRRSV than the wt PRRSV itself while 
the mutant FL-N34/51 induced six-fold higher (p<0.01) titer 
of wt PRRSV-neutralizing antibodies than wt PRRSV itself 
(Table 4B). 
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TABLE 4A 
Neutralizing antibody activity against 
Group FL12 at different times PI (days PI 
infected with O 14 21 48 
Wt PRRSVFL-12 1.0% 1.O 3.2 25.4 
FL-N34A 1.O 1.O 4.0 128.0 
FL-NS1A 1.O 1.O 4.0 128.0 
FL-N34,51A 1.O 1.O S.O 1613 
Table 4A. Effect of alteration of glycosylation pattern of PRRSV GP5 on the 
ability of the PRRSV strains to induce neutralizing antibodies to the wt 
PRRSV (4A) or to the infecting, homologous strain (4B) (*) Numbers in 
Table 4A and B correspond to geometric mean of the SN end-point for the 
group (n = 3). 
TABLE 4B 
End-point titer against the homologous 
Group infecting strain at different PI periods 
infected with O 14 21 48 
Wt PRRSVFL-12 1.O 1.O 3.2 25.4 
FL-N34A 1.O 4.0 128 8,192 
FL-NS1A 1.O 4.0 128 2,048 
FL-N34,51A 1.O 4.0 64 4,096 
Discussion 
In the present study, we examined the influence of glyco 
sylation of GP5 of PRRSV in recovery of infectious virus, its 
role in the ability of the mutant viruses to be neutralized by 
antibodies, and in inducing neutralizing antibodies in vivo. 
We have found that all three potential glycosylation sites 
(N34, N44, and N51) in GP5 are used for addition of glycan 
moieties. Our results reveal that glycan addition at N44 site is 
most critical for recovery of infectious virus. Furthermore, 
our results show that PRRSV containing hypoglycosylated 
forms of GP5 are exquisitely sensitive to neutralization by 
antibodies and that the mutant viruses induce significantly 
higher levels of neutralizing antibodies not only to the 
homologous mutant viruses but also to wt PRRSV. 
Confirmation that all three potential N-linked glycosyla 
tion sites are used for glycan addition in GP5 was provided by 
using mutants with alterations at single or multiple sites (FIG. 
2). Biochemical studies showed that the PRRSV GP5 protein 
when coexpressed with M protein in transfected cells, con 
tains Endo H sensitive high-mannose type glycans. The 
observation that majority of GP5 incorporated into virions is 
resistant to Endo H (FIG. 4A) whereas GP5 expressed in the 
presence of M protein in transfected cells is fully Endo H 
sensitive, is intriguing. It is possible that GP5 when expressed 
in the presence of M protein in transfected cells, accumulates 
mostly in the ER or in the cis-Golgi region and therefore 
remains Endo H sensitive. However, in PRRSV-infected 
cells, GP5 may interact with additional viral proteins and the 
transport of GP5 beyond ER or cis-Golgi is facilitated 
through formation of complexes with the other viral proteins. 
Consistent with this interpretation, we have observed that in 
wt or mutant PRRSV-infected cells, GP5 protein is also resis 
tant to Endo H. We suggest that GP5, which is synthesized in 
the ER in infected cells, is transported to the medial- and/or 
trans-Golgi regions where majority of GP5 molecules acquire 
Endo H resistance prior to being incorporated into PRRSV 
virions. Several studies with arteriviruses including PRRSV 
suggest that GP5 and M proteinform heterodimer, which may 
play a key role in viral infectivity. In EAV and LDV, direct 
interaction of GP5 and M protein through formation of dis 
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ulfide bridges have been demonstrated. Such interactions 
may occur prior to further processing of N-linked oligosac 
charide side chains, presumably before GP5 is transported out 
of the ER or the cis-Golgi compartment. 
It is interesting to note that the pattern of Endo H resistance 
of GP5 incorporated into wt and mutant virions is different. 
While the majority of GP5 molecules in wt PRRSV were 
Endo H resistant, most of GP5 molecules in the single site 
mutant virions (FL-N34A and FL-N51A) were Endo H sen 
sitive (FIG. 4A). Furthermore, of the two glycans moieties in 
these mutants, only one was sensitive while the other was 
resistant. The double mutant (FL-N34/51A) virion also incor 
porated GP5 that contained glycans, some of which were also 
sensitive to Endo H. These data are consistent with the inter 
pretation that wt as well as mutant PRRSV virions incorpo 
rate a mixed population of GP5 molecules that contain dif 
ferent glycan moieties at different sites. Previous studies 
demonstrating incorporation of differentially glycosylated 
forms of GP5 into wt PRRSV virions further strengthens our 
interpretation. From the pattern of Endo H sensitivity of GP5 
incorporated into the virions, it is tempting to speculate that 
N44 site may contain the Endo H resistant glycans, although 
some GP5 molecules with Endo H sensitive glycans at this 
site were incorporated into the virions. Whether this unusual 
pattern of glycans at various sites in GP5 and incorporation of 
various forms of GP5 into virions has any relevance to the 
pattern of immune response seen in PRRSV infected animals 
remains to be investigated. 
In a recent study, it was shown that of the two N-linked 
glycosylation sites (N46 and N53) in GP5 of Lelystad 
PRRSV, glycosylation of N46 residue was strongly required 
for virus particle production. Infectious virus yield was 
reduced by approximately 100-fold with mutation at N46. 
Our results suggest that glycan addition at N44 (for North 
American PRRSV) is absolutely essential for recovery of 
infectious PRRSV. It is possible then that the European and 
North American isolates of PRRSV may somewhat differ in 
their requirements for N-linked glycosylation for production 
of infectious viruses. In this regard, it is of note that the 
Lelystad virus contains only two N-linked glycosylation sites 
whereas the North American isolate we have used in this 
study contain three such sites. 
The GP5 is the most important glycoprotein of PRRSV 
involved in the generation of PRRSV-neutralizing antibodies 
and protective immunity. Our results reveal that the absence 
of glycans at residues 34 and 51 in the GP5 ectodomain, while 
generating viable PRRSV mutants, enhance both the sensi 
tivity of these mutants to neutralization by antibodies as well 
as the immunogenicity of the nearby neutralization epitope. 
The immediate effect of the absence of glycans in GP5 of 
mutant PRRSVs has been the increased sensitivity of the 
viruses to neutralization by convalescent Sera from pigs 
infected with wt PRRSV (Table 3). Studies with HIV-1 and 
SIV have shown that acquisition or removal of glycans in the 
variable loops of gp160 modify their sensitivity to neutraliza 
tion. Therefore, it has been postulated that glycans play at 
least two types of essential roles during viral envelope glyco 
protein biosynthesis. In one case, lack of glycans entails 
defects of the glycoprotein and thus, in the overall viability of 
the viral strain. We postulate that glycans at N44 of PRRSV 
GP5 serve a similar role. In the second case, the glycans 
potentially serve to shield viral proteins against neutralization 
by antibodies. For PRRSV GP5, glycans at N34 and N51 may 
have a similar role. In the case of HIV. “glycan shielding is 
postulated to be a primary mechanism to explain evasion from 
neutralizing immune response, thus ensuring in vivo persis 
tence of HIV. This invites to draw some parallel comparisons 
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with the PRRSV. Infection with PRRSV, which is known to 
persist for several months in individual animals, presents an 
unusual behavior in terms of induction of virus-specific neu 
tralizing immune response. It is well established that animals 
infected with PRRSV usually take longer than normal time to 
establish a detectable PRRSV-neutralizing antibody 
response. Once established, this PRRSV-neutralizing 
response is weak, and varies significantly from animal to 
animal. The delay in neutralizing antibody response has been 
postulated to be due to the presence of a nearby immunodomi 
nant decoy epitope (amino acid positions 27 to 30), which 
evokes a robust, early, non-protective immune response that 
masks and/or slows the response to the neutralizing epitope 
(amino acid position 37 to 45) (26, 38). While this being a 
plausible explanation for the atypical character of the 
PRRSV-neutralizing antibody response, it remains to be 
tested. In our laboratory, deletion of the decoy epitope has 
consistently proven lethal to the recovery of infectious 
PRRSV (Ansari et al., unpublished data), thus making it 
difficult to test this hypothesis. 
It is possible that an alternative or complementary mecha 
nism to explain the peculiar nature of the PRRSV-neutraliz 
ing response could be envisioned by the “glycan shielding 
phenomenon proposed for HIV and SIV. The use of mutant 
PRRSVs lacking one or two glycan moieties in our studies 
provides evidence for the first time the presence of large 
amounts of PRRSV neutralizing antibodies in the sera of wt 
PRRSV-infected animals that were otherwise undetectable 
because of the use of wt PRRSV in the SN assays. The 
PRRSV-neutralizing antibodies, while present in the hosts 
response, are unable to react with the infecting wt PRRSV 
virions due to the blocking or shielding of the neutralizing 
epitope by the glycan moieties on GP5. 
One important precedent for neutralization escape by gly 
cosylation of glycoproteins in arteriviruses has been 
described for lactate dehydrogenase-elevating virus (LDV). 
LDV is highly resistant to antibody neutralization due to the 
heavy glycan shielding of their major glycoprotein, VP-3, 
however, certain naturally occurring strains of LDV are 
highly susceptible to neutralization, due to loss of two glyco 
sylation sites on the ectodomain of the VP-3. Interestingly, 
this neutralization-sensitive phenotype correlates with a high 
degree of neurotropism in the host acquired by these easily 
neutralizable LDV strains. Such neuropathogenicity 
enhancement probably reflects the facilitation of interaction 
of the viral glycoproteins with receptors in neural cells, pos 
sibly due to the absence of glycan shielding. In the young pig 
model that we used for inoculation with PRRSV, we were not 
able to detect pathogenic differences between any of the 
mutant PRRSVs and the wt PRRSV, although we limited our 
observations to temperature and viremia measurements. It is 
possible that under different experimental conditions (i.e., in 
a pregnant sow model). Some alterations in pathogenicity of 
these mutant PRRSVs might be observed. It is not known 
whether the finding of naturally occurring hypoglycosylated 
PRRSV strains is a common occurrence, although previous 
reports have suggested their presence. 
A remarkable observation in our experiments has been that 
the GP5 mutants, when infecting pigs in Vivo, can outperform 
the wt PRRSV in their ability to mount a sizable wt PRRSV 
neutralizing response at late phases of infection (Table 4A). 
In a parallel scenario, we have observed not only higher 
neutralizing titers against homologous PRRSV mutants but 
also sizable titers against wt PRRSV (Table 4A). In addition, 
the response occurred earlier, with neutralizing titers detect 
able at 14 days p.i., an observation not typically noted with wit 
PRRSV infection (Table 4B). The increased neutralization of 
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wt PRRSV by sera from pigs infected with the PRRSV 
mutants Suggests that glycans were masking neutralizing 
epitope(s) that do not induce neutralizing antibodies when 
glycans are present. This observation has great significance 
on the design of better, more efficacious PRRSV vaccines, 
Suggesting that new, rationally-designed vaccines should 
carry modifications in the glycosylation pattern of GP5 in 
order to enhance the production of neutralizing antibodies. In 
addition, it will be important to study the effects that this 
removal of carbohydrates from immunologically prominent 
glycoproteins of PRRSV may have on increasing SN titers 
not only to the homologous immunizing strain but also to 
diverse unrelated PRRSV Strains. 
Example 2 
Identification of N-Linked Glycosylation Sites in 
North American and European PRRSV. Isolates 
To identify N-linked glycosylation sites corresponding to 
asparagine 34 or asparagine 51 in a reference GP5 protein of 
SEQID NO:1 that can be inactivated and used in the methods 
of this invention, the GP5 proteins of either a desired North 
American PRRSV isolate (FIG. 5) or a European PRRSV 
isolate (FIG. 6) are aligned with reference GP5 protein of 
SEQ ID NO: 1 (North American strain NVSL 97-7895). In 
this example, the alignments were created with the MegA 
lignTM program from DNASTAR, Inc. (Madison, Wis., USA) 
using the Jotun-Hein method of alignment (Hein, J. J. In 
Methods in Enzymology, Vol. 183: pp. 626-645, 1990). Mul 
tiple sequence alignment parameters were a gap penalty of 11 
and a gap length penalty of 3. For pairwise comparisons, a 
Ktuple value of 2 was used. 
In FIG. 5, it is clear that the N-linked glycosylation site 
corresponding to asparagine 51 of the reference GP5 protein 
of SEQID NO:1 present in all of the North American PRRSV 
isolates shown and comprises the N-linked glycosylation site 
“NGT. This N-linked glycosylation site can be inactivated 
by Substituting codons encoding other amino acid residues 
Such as glutamine or alanine for asparagine 51 in the corre 
sponding polynucleotide sequence. In these instances, the 
corresponding amino acid sequence in the hypoglycosylated 
North American PRRSV GP5 protein variant would comprise 
the sequences such as “QGT”, “AGT', or “XGT, where X is 
any amino acid other than asparagine. These or other 
hypoglycosylated variants of the North American PRRSV 
isolates where N-linked glycosylation site corresponding to 
asparagine 51 is inactivated can also be combined with other 
hypoglycosylated GP5 variants where other N-linked glyco 
Sylation sites are inactivated. 
It is also clear from FIG. 5, that the N-linked glycosylation 
site corresponding exactly to asparagine 34 of the reference 
GP5 protein of SEQID NO:1 is present in only certain North 
American PRRSV isolates. More specifically, the GP5 pro 
teins of North American PRRSV isolates IAF-BAJ (SEQ ID 
NO:3), 94-3182 (SEQID NO:7), and 94-287 (SEQID NO:8) 
contain the N-linked glycosylation site corresponding exactly 
to asparagine 34 of the reference GP5 protein of SEQ ID 
NO:1 and comprises the N-linked glycosylation site “NSS'. 
This N-linked glycosylation site of SEQ ID NO:3, 7, and 8 
can be inactivated by Substituting codons encoding other 
amino acid residues such as glutamine or alanine for aspar 
agine 34 in the corresponding polynucleotide sequence. In 
these instances, the corresponding amino acid sequence in the 
hypoglycosylated North American PRRSV GP5 protein vari 
ant would comprise the sequences such as “QSS', 'ASS, or 
“XSS, where X is any amino acid other than asparagine. 
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In other North American PRRSV isolates that lack the 
N-linked glycosylation site corresponding exactly to aspar 
agine 34 of the reference GP5 protein of SEQID NO:1, other 
N-linked glycosylation sites located at residue 30 (FIG. 5 
“NAS” in SEQID NO:2, 3, 4, 6, 7, 8, 9, 11, 13), and residue 
33 (FIG. 5 “NNS” in SEQID NO:3, 8: “NSS” in SEQ ID 
NO:6, 10, “NDS” in SEQID NO:11, 13) can also be inacti 
vated. In other words, N-linked glycosylation sites in other 
North American isolates located at amino acid positions cor 
responding to residues 30 and 33 of the reference GP5 protein 
of SEQ ID NO:1 can also be inactivated and used in the 
methods of this invention. 
In FIG. 6, it is clear that the N-linked glycosylation site 
corresponding to asparagine 51 of the reference GP5 protein 
of SEQID NO:1 is also present in a representative European 
PRRSV isolate and comprises the N-linked glycosylation site 
“NGT. This N-linked glycosylation site can be inactivated 
by Substituting codons encoding other amino acid residues 
Such as glutamine or alanine for asparagine 51 in the corre 
sponding polynucleotide sequence. In these instances, the 
corresponding amino acid sequence in the hypoglycosylated 
European PRRSV GP5 protein variant would comprise the 
sequences such as “QGT, “AGT', or “XGT, where X is any 
amino acid other than asparagine. These or other hypoglyco 
sylated variants of the European PRRSV isolates where 
SEQUENCE LISTING 
<16 Oc NUMBER OF SEO ID NOS: 26 
<21 Oc 
<211 
<212 
SEO ID NO 1 
LENGTH: 2OO 
TYPE PRT 
<4 OO SEQUENCE: 1 
Met Lieu. Gly Arg Cys Lieu. Thir Ala Ser 
1. 5 
Gly Cys Cys 
Ile Wall Phe Phe Ala Ala Pro Luell 
25 
Luell 
2O 
Trp. Cys 
His Lieu. Glin Lieu. Ile Asn 
4 O 
Ser Asn. Ser Ser Ser 
35 
Tyr 
45 
Glu 
SO 
Lieu. Asn Gly. Thir Asp Lell Phe 
55 
Trp Lys Asp Llys 
60 
Glu 
65 
Thir Phe Wall Ile Phe 
70 
Wall Thir His Ile Pro Lell 
Ala 
85 
Thir Thr Phe Thir Wall 
95 
His Lell 
90 
Lell Ser Asp Gly 
Thir Ala Phe Wall 
10 
Ser His Luell 
OO 
Gly Gly Arg Tyr 
O5 
Val Cys Ala Lieu. Ala Lieu. Ile Wall 
Asn Cys Met Ser T Arg Ser Arg 
Lieu. Asp Thir Lys Arg Lieu. Tyr Arg T Arg 
Glu Lys Gly Gly Wall Glu Wall Glu His 
Arg Val Val Lieu. Gly Ser Val Ala T Pro 
Wall 
Luell 
Asp 
Wall 
Luell 
Ser 
Ile 
Ser 
Luell 
Luell 
10 
15 
Arg Lieu. 
ASn 
Thir 
Trp 
Ser 
Wall 
Ser 
Arg 
Thir 
Pro 
le 
Thir 
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N-linked glycosylation site corresponding to asparagine 51 is 
inactivated can also be combined with other hypoglycosy 
lated GP5 variants where other N-linked glycosylation sites 
are inactivated. 
In view of the foregoing, it will be seen that the several 
advantages of the invention are achieved and attained. 
The embodiments were chosen and described in order to 
best explain the principles of the invention and its practical 
application to thereby enable others skilled in the art to best 
utilize the invention in various embodiments and with various 
modifications as are Suited to the particular use contemplated. 
AS Various modifications could be made in the construc 
tions and methods herein described and illustrated without 
departing from the scope of the invention, it is intended that 
all matter contained in the foregoing description or shown in 
the accompanying drawings shall be interpreted as illustrative 
rather than limiting. Thus, the breadth and scope of the 
present invention should not be limited by any of the above 
described exemplary embodiments, but should be defined 
only in accordance with the following claims appended 
hereto and their equivalents. 
A variety of patent and non-patent references are disclosed 
herein, each of which is expressly incorporated herein by 
reference in their entirety. 
ORGANISM: Porcine reproductive and respiratory syndrome virus 
Luell Ser 
15 
Ala Asn 
Lell 
Ala Wall 
Tyr Gly 
Thir Wall 
Ile 
Lieu Ala 
Asn. Phe 
Wall Ile 
16 O 
Asp Lieu. 
Wall 
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Ser Ala Glu Gln Trp Gly Arg Lieu 
195 2 OO 
<210 SEQ ID NO 2 
<211 LENGTH: 2OO 
&212> TYPE: PRT 
<213> ORGANISM: Porcine reproductive and respiratory syndrome virus 
<4 OO SEQUENCE: 2 
Met Leu Gly Lys Cys Lieu. Thir Ala Gly Cys Cys Ser Gln Leu Pro Phe 
1. 5 1O 15 
Lieu. Trp Cys Ile Val Pro Phe Cys Phe Ala Ala Lieu Val Asn Ala Ser 
2O 25 3 O 
Ser Ser Ser Ser Ser Gln Leu Glin Ser Ile Tyr Asn Lieu. Thir Ile Cys 
35 4 O 45 
Glu Lieu. Asn Gly Thr Asp Trp Lieu. Asn Lys Asn. Phe Asp Trp Ala Val 
SO 55 6 O 
Glu Thr Phe Val Ile Phe Pro Val Lieu. Thr His Ile Val Ser Tyr Gly 
65 70 7s 8O 
Ala Lieu. Thir Thr Ser His Phe Lieu. Asp Ala Val Gly Lieu. Ile Thr Val 
85 9 O 95 
Ser Thr Ala Gly Tyr Tyr His Gly Arg Tyr Val Lieu Ser Ser Val Tyr 
OO OS 1O 
Ala Val Cys Ala Lieu Ala Ala Lieu. Ile Cys Phe Val Ile Arg Lieu. Thr 
15 2O 25 
Lys Asn Cys Met Ser Trp Arg Tyr Ser Cys Thr Arg Tyr Thr Asn Phe 
3O 35 4 O 
Lieu. Lieu. Asp Ser Lys Gly Llys Lieu. Tyr Arg Trp Arg Ser Pro Val Ile 
45 SO 55 160 
le Glu Lys Gly Gly Llys Val Glu Val Asp Gly His Lieu. Ile Asp Lieu 
65 70 7s 
Lys Arg Val Val Lieu. Asp Gly Ser Ala Ala Thr Pro Val Thir Lys Val 
8O 85 90 
Ser Ala Glu Gln Trp Cys Arg Pro 
95 2 OO 
<210 SEQ ID NO 3 
<211 LENGTH: 2OO 
&212> TYPE: PRT 
<213> ORGANISM: Porcine reproductive and respiratory syndrome virus 
<4 OO SEQUENCE: 3 
Met Leu Gly Lys Cys Lieu. Thir Ala Gly Cys Cys Ser Gln Leu Pro Phe 
1. 5 1O 15 
Lieu. Trp Cys Ile Val Pro Phe Cys Phe Ala Ala Lieu Val Asn Ala Ser 
2O 25 3 O 
Asn Asn Ser Ser Ser Gln Leu Glin Ser Ile Tyr Asn Lieu. Thir Ile Cys 
35 4 O 45 
Glu Lieu. Asn Gly Thr Asp Trp Lieu. Asn Lys Asn. Phe Asp Trp Ala Val 
SO 55 6 O 
Glu Thr Phe Val Ile Phe Pro Val Lieu. Thr His Ile Val Ser Tyr Gly 
65 70 7s 8O 
Ala Lieu. Thir Thr Ser His Phe Lieu. Asp Thr Val Gly Lieu. Ile Thr Val 
85 9 O 95 
Ser Thr Ala Gly Tyr Tyr His Gly Arg Tyr Val Lieu Ser Ser Val Tyr 
1 OO 105 11O 
34 
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Ala Val Cys Ala Lieu Ala Ala Lieu. Ile Cys Phe Val Ile Arg Lieu. Thr 
15 12O 125 
Lys Asn Cys Met Ser Trp Arg Tyr Ser Cys Thr Arg Tyr Thr Asn Phe 
3O 135 14 O 
Lieu. Lieu. Asp Ser Lys Gly Llys Lieu. Tyr Arg Trp Arg Ser Pro Val Ile 
45 150 155 160 
le Glu Lys Gly Gly Llys Val Glu Val Asp Gly His Lieu. Ile Asp Lieu 
65 17O 17s 
Lys Arg Val Val Lieu. Asp Gly Ser Ala Ala Thr Pro Val Thir Lys Val 
8O 185 190 
Ser Ala Glu Gln Trp Cys Arg Pro 
95 2 OO 
<210 SEQ ID NO 4 
<211 LENGTH: 2OO 
&212> TYPE: PRT 
<213> ORGANISM: Porcine reproductive and respiratory syndrome virus 
<4 OO SEQUENCE: 4 
Met Leu Gly Lys Cys Lieu. Thr Val Gly Tyr Cys Ser Gln Leu Pro Phe 
1. 5 1O 15 
Lieu. Trp Cys Ile Val Pro Phe Cys Phe Ala Ala Lieu Val Asn Ala Ser 
2O 25 3 O 
Ser Thr Ser Ser Ser His Leu Gln Lieu. Ile Tyr Asn Lieu. Thir Ile Cys 
35 4 O 45 
Glu Lieu. Asn Gly Thr Asp Trp Lieu. Asn. Glu, Llys Phe Asp Trp Ala Val 
SO 55 6 O 
Glu Thr Phe Val Ile Phe Pro Val Lieu. Thr His Ile Val Ser Tyr Gly 
65 70 7s 8O 
Ala Lieu. Thir Thr Ser His Phe Lieu. Asp Thr Val Gly Lieu Val Thr Val 
85 9 O 95 
Ser Thr Ala Gly Tyr Tyr His Gly Arg Tyr Val Lieu Ser Ser Ile Tyr 
OO OS 1O 
Ala Val Cys Ala Lieu Ala Ala Lieu. Ile Cys Phe Val Ile Arg Lieu Val 
15 2O 25 
Lys Asn Cys Met Ser Trp Arg Tyr Ser Cys Thr Arg Tyr Thr Asn Phe 
3O 35 4 O 
Lieu. Lieu. Asp Thir Lys Gly Llys Lieu. Tyr Arg Trp Arg Ser Pro Val Ile 
45 SO 55 160 
Val Glu Lys Arg Gly Llys Val Glu Val Gly Gly His Lieu. Ile Asp Lieu 
65 70 7s 
Lys Arg Val Val Lieu. Asp Gly Ser Ala Ala Thr Pro Val Thir Arg Val 
8O 85 90 
Ser Ala Glu Gln Trp Gly Arg Pro 
<210 SEQ ID NO 5 
<211 LENGTH: 2OO 
&212> TYPE: PRT 
<213> ORGANISM: Porcine reproductive and respiratory syndrome virus 
<4 OO SEQUENCE: 5 
Met Leu Gly Lys Cys Lieu. Thir Ala Gly Cys Cys Ser Gln Leu Pro Phe 
1. 5 1O 15 
Lieu. Trp Cys Ile Val Pro Phe Cys Phe Val Ala Lieu Val Asn Ala Asn 
2O 25 3 O 
36 
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Thr Asp Ser Ser Ser His Leu Gln Lieu. Ile Tyr Asn Lieu. Thir Ile Cys 
35 4 O 45 
Glu Lieu. Asn Gly Thr Asp Trp Lieu. Asn Asp Llys Phe Asp Trp Ala Val 
SO 55 6 O 
Glu Thr Phe Val Ile Phe Pro Val Lieu. Thr His Ile Val Ser Tyr Gly 
65 70 7s 8O 
Ala Lieu. Thir Thr Ser His Phe Lieu. Asp Thr Val Gly Lieu. Ile Thr Val 
85 9 O 95 
Ser Thr Ala Gly Tyr Tyr His Gly Arg Tyr Val Lieu Ser Ser Ile Tyr 
OO OS 1O 
Ala Val Cys Ala Lieu Ala Ala Lieu. Ile Cys Phe Ala Ile Arg Lieu. Thr 
15 2O 25 
Lys Asn Cys Met Ser Trp Arg Tyr Ser Cys Thr Arg Tyr Thr Asn Phe 
3O 35 4 O 
Lieu. Lieu. Asp Thir Lys Gly Llys Lieu. Tyr Arg Trp Arg Ser Pro Val Ile 
45 SO 55 160 
le Glu Arg Glin Gly Llys Val Glu Val Glu Gly His Lieu. Ile Asp Lieu 
Lys Arg Val Val Lieu. Asp Gly Ser Ala Ala Thr Pro Val Thir Arg Val 
Ser Ala Glu Arg Trp Gly Arg Pro 
95 2 OO 
<210 SEQ ID NO 6 
<211 LENGTH: 2OO 
&212> TYPE: PRT 
<213> ORGANISM: Porcine reproductive and respiratory syndrome virus 
<4 OO SEQUENCE: 6 
Met Lieu. Gly Lys Cys Lieu. Thir Ala Gly Cys Cys Ser Arg Lieu Pro Phe 
1. 5 1O 15 
Lieu. Trp Cys Ile Val Pro Phe Cys Phe Ala Ala Lieu Val Asn Ala Ser 
2O 25 3 O 
Asn Ser Ser Ser Ser His Leu Gln Lieu. Ile Tyr Asn Lieu. Thir Ile Cys 
35 4 O 45 
Glu Lieu. Asn Gly Thr Asp Trp Lieu. Asp Llys Llys Phe Asp Trp Ala Val 
SO 55 6 O 
Glu Thr Phe Val Ile Phe Pro Val Lieu. Thr His Ile Val Ser Tyr Gly 
65 70 7s 8O 
Ala Lieu. Thir Thr Ser His Phe Lieu. Asp Thr Val Gly Lieu. Ile Thr Val 
85 9 O 95 
Ser Thr Ala Gly Tyr Tyr His Gly Arg Tyr Val Lieu Ser Ser Ile Tyr 
OO OS 1O 
Ala Val Cys Ala Lieu Ala Ala Lieu. Ile Cys Phe Val Ile Arg Lieu. Thr 
15 2O 25 
Lys Asn Cys Met Ser Trp Arg Tyr Ser Cys Thr Arg Tyr Thr Asn Phe 
3O 35 4 O 
Lieu. Lieu. Asp Thir Lys Gly Llys Lieu. Tyr Arg Trp Arg Ser Pro Val Ile 
45 SO 55 160 
le Glu Lys Arg Gly Llys Val Glu Val Glu Gly Glin Lieu. Ile Asp Lieu 
65 70 7s 
Lys Arg Val Val Lieu. Asp Gly Ser Ala Ala Thr Pro Ile Thir Lys Val 
8O 85 90 
Ser Ala Glu Gln Trp Gly Arg Pro 
38 
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195 2 OO 
<210 SEQ ID NO 7 
<211 LENGTH: 2OO 
&212> TYPE: PRT 
<213> ORGANISM: Porcine reproductive and respiratory syndrome virus 
<4 OO SEQUENCE: 7 
Met Lieu. Gly Lys Cys Lieu. Thir Ala Gly Cys Cys Ser Arg Lieu Pro Phe 
1. 5 1O 15 
Lieu. Trp Cys Ile Val Pro Phe Cys Phe Ala Val Lieu Val Asn Ala Ser 
2O 25 3 O 
Pro Asn Ser Ser Ser His Leu Gln Lieu. Ile Tyr Asn Lieu. Thir Ile Cys 
35 4 O 45 
Glu Lieu. Asn Gly Thr Asp Trp Lieu. Asn Ala Arg Phe Asp Trp Ala Val 
SO 55 6 O 
Glu Thr Phe Val Ile Phe Pro Val Val Thr His Ile Val Ser Tyr Gly 
65 70 7s 8O 
Ala Lieu. Thir Thr Ser His Phe Lieu. Asp Thr Val Gly Lieu Val Thr Val 
85 9 O 95 
Ser Thr Ala Gly Tyr Tyr His Gly Arg Tyr Val Lieu Ser Ser Ile Tyr 
OO OS 1O 
Ala Val Cys Ala Lieu Ala Ala Lieu. Ile Cys Phe Val Ile Arg Lieu Ala 
15 2O 25 
Lys Asn Cys Met Ser Trp Arg Tyr Ser Cys Thr Arg Tyr Thr Asn Phe 
3O 35 4 O 
Lieu. Lieu. Asp Thir Lys Gly Llys Lieu. Tyr Arg Trp Arg Ser Pro Val Ile 
45 SO 55 160 
le Glu Lys Arg Gly Llys Val Glu Val Glu Gly His Lieu. Ile Asp Lieu 
Lys Arg Val Val Lieu. Asp Gly Ser Ala Ala Thr Pro Val Thir Arg Val 
Ser Ala Glu Gln Trp Cys Arg Pro 
95 2 OO 
<210 SEQ ID NO 8 
<211 LENGTH: 2OO 
&212> TYPE: PRT 
<213> ORGANISM: Porcine reproductive and respiratory syndrome virus 
<4 OO SEQUENCE: 8 
Met Leu Gly Lys Cys Lieu. Thir Ala Gly Cys Cys Ser Gln Leu Pro Phe 
1. 5 1O 15 
Lieu. Trp Cys Ile Val Pro Phe Cys Phe Ala Ala Lieu Val Asn Ala Ser 
2O 25 3 O 
Asn Asn. Ser Ser Ser His Lieu. Glin Lieu. Ile Tyr Asn Lieu. Thir Ile Cys 
35 4 O 45 
Glu Lieu. Asn Gly Thr Asp Trp Lieu. Asn Asp Llys Phe Asp Trp Ala Val 
SO 55 6 O 
Glu Thr Phe Val Ile Phe Pro Val Lieu. Thr His Ile Val Ser Tyr Gly 
65 70 7s 8O 
Ala Lieu. Thir Thr Ser His Phe Lieu. Asp Thr Val Gly Lieu. Ile Thr Val 
85 9 O 95 
Ser Thr Ala Gly Tyr Tyr His Gly Arg Tyr Val Lieu Ser Ser Ile Tyr 
1 OO 105 11O 
Ala Val Cys Ala Lieu Ala Ala Lieu. Ile Cys Phe Val Ile Arg Lieu Ala 
40 
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15 12O 125 
Lys Asn Cys Met Ser Trp Arg Tyr Ser Cys Thr Arg Tyr Thr Asn Phe 
3O 135 14 O 
Lieu. Lieu. Asp Thir Lys Gly Arg Lieu. Tyr Arg Trp Arg Ser Pro Val Ile 
45 150 155 160 
le Glu Lys Lys Gly Llys Val Glu Val Glu Gly Glin Lieu. Ile Asp Lieu 
65 17O 17s 
Lys Arg Val Val Lieu. Asp Gly Ser Ala Ala Thr Pro Ile Thir Arg Val 
8O 185 190 
Ser Ala Glu Gln Trp Gly Arg Pro 
95 2 OO 
<210 SEQ ID NO 9 
<211 LENGTH: 2OO 
&212> TYPE: PRT 
<213> ORGANISM: Porcine reproductive and respiratory syndrome virus 
<4 OO SEQUENCE: 9 
Met Leu Gly Lys Cys Lieu. Thir Ala Gly Cys Cys Ser Gln Leu Pro Phe 
1. 5 1O 15 
Lieu. Trp Cys Ile Val Pro Phe Cys Phe Ala Ala Lieu Val Asn Ala Ser 
2O 25 3 O 
Ser Ser Ser Ser Ser Gln Leu Glin Ser Ile Tyr Asn Lieu. Thir Ile Cys 
35 4 O 45 
Glu Lieu. Asn Gly Thr Asp Trp Lieu. Asn Lys Asn. Phe Asp Trp Ala Val 
SO 55 6 O 
Glu Thr Phe Val Ile Phe Pro Val Lieu. Thr His Ile Val Ser Tyr Gly 
65 70 7s 8O 
Ala Lieu. Thir Thr Ser His Phe Lieu. Asp Ala Val Gly Lieu. Ile Thr Val 
85 9 O 95 
Ser Thr Ala Gly Tyr Tyr His Gly Arg Ser Val Lieu Ser Ser Val Tyr 
OO OS 1O 
Ala Val Cys Ala Lieu Ala Ala Lieu. Ile Cys Phe Val Ile Arg Lieu. Thr 
15 2O 25 
Lys Asn Cys Met Ser Trp Arg Tyr Ser Cys Thr Arg Tyr Thr Asn Phe 
3O 35 4 O 
Lieu. Lieu. Asp Ser Lys Gly Llys Lieu. Tyr Arg Trp Arg Ser Pro Val Ile 
45 SO 55 160 
le Glu Lys Gly Gly Llys Val Glu Val Asp Gly His Lieu. Ile Asp Lieu 
65 70 7s 
Lys Arg Val Val Lieu. Asp Gly Ser Ala Ala Thr Pro Val Thir Lys Val 
Ser Ala Glu Gln Trp Cys Arg Pro 
95 2 OO 
<210 SEQ ID NO 10 
<211 LENGTH: 2OO 
&212> TYPE: PRT 
<213> ORGANISM: Porcine reproductive and respiratory syndrome virus 
<4 OO SEQUENCE: 10 
Met Lieu. Gly Lys Cys Lieu. Thir Ala Gly Cys Cys Ser Glin Lieu. Lieu. Phe 
1. 5 1O 15 
Lieu. Trp Cys Ile Val Pro Ser Trp Phe Val Ala Leu Val Ser Ala Ser 
2O 25 3 O 
Asn Ser Ser Ser Ser His Lieu. Glin Lieu. Ile Tyr Asn Lieu. Thir Lieu. Cys 
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35 4 O 45 
Glu Lieu. Asn Gly Thr Asp Trp Lieu Ala Asp Llys Phe Asp Trp Ala Val 
SO 55 6 O 
Glu Thr Phe Val Ile Phe Pro Val Lieu. Thr His Ile Val Ser Tyr Gly 
65 70 7s 8O 
Ala Lieu. Thir Thr Ser His Phe Lieu. Asp Thr Val Gly Lieu Val Thr Val 
85 9 O 95 
Ser Thr Ala Gly Phe His His Gly Arg Tyr Val Lieu Ser Ser Ile Tyr 
OO OS 1O 
Ala Val Cys Ala Lieu Ala Ala Lieu. Ile Cys Phe Val Ile Arg Lieu Ala 
15 2O 25 
Lys Asn Cys Met Ser Trp Arg Tyr Ser Cys Thr Arg Tyr Thr Asn Phe 
3O 35 4 O 
Lieu. Lieu. Asp Thir Lys Gly Arg Lieu. Tyr Arg Trp Arg Ser Pro Val Ile 
45 SO 55 160 
le Glu Lys Gly Gly Llys Val Glu Val Glu Gly His Lieu. Ile Asp Lieu 
65 70 7s 
Lys Arg Val Val Lieu. Asp Gly Ser Val Ala Thr Pro Ile Thir Arg Val 
Ser Ala Glu Gln Trp Gly Arg Pro 
<210 SEQ ID NO 11 
<211 LENGTH: 2OO 
&212> TYPE: PRT 
<213> ORGANISM: Porcine reproductive and respiratory syndrome virus 
<4 OO SEQUENCE: 11 
Met Lieu. Glu Lys Cys Lieu. Thir Ala Gly Cys Cys Ser Arg Lieu. Lieu. Ser 
1. 5 1O 15 
Lieu. Trp Cys Ile Val Pro Phe Cys Phe Ala Val Lieu Ala Asn Ala Ser 
2O 25 3 O 
Asn Asp Ser Ser Ser His Lieu. Glin Lieu. Ile Tyr Asn Lieu. Thir Lieu. Cys 
35 4 O 45 
Glu Lieu. Asn Gly Thr Asp Trp Lieu Ala Asn Llys Phe Asp Trp Ala Val 
SO 55 6 O 
Glu Ser Phe Val Ile Phe Pro Val Lieu. Thr His Ile Val Ser Tyr Gly 
65 70 7s 8O 
Ala Lieu. Thir Thr Ser His Phe Lieu. Asp Thr Val Ala Leu Val Thr Val 
85 9 O 95 
Ser Thr Ala Gly Phe Val His Gly Arg Tyr Val Lieu Ser Ser Ile Tyr 
OO OS 1O 
Ala Val Cys Ala Lieu Ala Ala Lieu. Thir Cys Phe Val Ile Arg Phe Ala 
15 2O 25 
Lys Asn Cys Met Ser Trp Arg Tyr Ala Cys Thr Arg Tyr Thr Asn Phe 
3O 35 4 O 
Lieu. Lieu. Asp Thir Lys Gly Arg Lieu. Tyr Arg Trp Arg Ser Pro Val Ile 
45 SO 55 160 
le Glu Lys Arg Gly Llys Val Glu Val Glu Gly His Lieu. Ile Asp Lieu 
65 70 7s 
Lys Arg Val Val Lieu. Asp Gly Ser Val Ala Thr Pro Ile Thir Arg Val 
Ser Ala Glu Gln Trp Gly Arg Pro 
95 2 OO 
44 
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<210 SEQ ID NO 12 
<211 LENGTH: 2OO 
&212> TYPE: PRT 
<213> ORGANISM: Porcine reproductive and respiratory syndrome virus 
<4 OO SEQUENCE: 12 
Met Lieu. Gly Lys Cys Lieu. Thir Ala Gly Cys Cys Ser Glin Lieu. Lieu. Phe 
1. 5 1O 15 
Lieu. Trp Cys Ile Val Pro Ser Cys Phe Val Ala Lieu Val Ser Ala Asn 
2O 25 3 O 
Gly Asn. Ser Gly Ser Asn Lieu. Glin Lieu. Ile Tyr Asn Lieu. Thir Lieu. Cys 
35 4 O 45 
Glu Lieu. Asn Gly Thr Asp Trp Lieu Ala Asn Llys Phe Asp Trp Ala Val 
SO 55 6 O 
Glu Cys Phe Val Ile Phe Pro Val Lieu. Thr His Ile Val Ser Tyr Gly 
65 70 7s 8O 
Ala Lieu. Thir Thr Ser His Phe Lieu. Asp Thr Val Gly Lieu Val Thr Val 
85 9 O 95 
Ser Thr Ala Gly Phe Val His Gly Arg Tyr Val Lieu Ser Ser Met Tyr 
OO OS 1O 
Ala Val Cys Ala Lieu Ala Ala Lieu. Ile Cys Phe Val Ile Arg Lieu Ala 
15 2O 25 
Lys Asn Cys Met Ser Trp Arg Tyr Ser Cys Thr Arg Tyr Thr Asn Phe 
3O 35 4 O 
Lieu. Lieu. Asp Thr Lys Gly Arg Lieu. Tyr Arg Trp Arg Ser Pro Val Ile 
45 SO 55 160 
le Glu Lys Arg Gly Llys Val Glu Val Glu Gly His Lieu. Ile Asp Lieu 
65 70 7s 
Lys Arg Val Val Lieu. Asp Gly Ser Ala Ala Thr Pro Val Thir Arg Val 
Ser Ala Glu Gln Trp Ser Arg Pro 
95 2 OO 
<210 SEQ ID NO 13 
<211 LENGTH: 2OO 
&212> TYPE: PRT 
<213> ORGANISM: Porcine reproductive and respiratory syndrome virus 
<4 OO SEQUENCE: 13 
Met Lieu. Glu Lys Cys Lieu. Thir Ala Gly Cys Cys Ser Glin Lieu. Lieu. Ser 
1. 5 1O 15 
Lieu. Trp Cys Ile Val Pro Phe Cys Phe Ala Val Lieu Ala Asn Ala Ser 
2O 25 3 O 
Asn Asp Ser Ser Ser His Lieu. Glin Lieu. Ile Tyr Asn Lieu. Thir Lieu. Cys 
35 4 O 45 
Glu Lieu. Asn Gly Thr Asp Trp Lieu Ala Asn Llys Phe Asp Trp Ala Val 
SO 55 6 O 
Glu Ser Phe Val Ile Phe Pro Val Lieu. Thr His Ile Val Ser Tyr Gly 
65 70 7s 8O 
Ala Lieu. Thir Thr Ser His Phe Lieu. Asp Thr Val Ala Leu Val Thr Val 
85 9 O 95 
Ser Thr Ala Gly Phe Val His Gly Arg Tyr Val Lieu Ser Ser Ile Tyr 
1 OO 105 11O 
Ala Val Cys Ala Lieu Ala Ala Lieu. Thir Cys Phe Val Ile Arg Phe Ala 
115 12O 125 
46 
Lys 
13 O 
Asn Cys 
Lieu. Lieu. Asp 
145 
Ile 
1.65 
Lys 
18O 
Ser 
195 
Glu 
Arg 
Ala 
Lys 
Wall 
Glu 
Met Ser 
Thr Lys 
Arg Gly 
Wall Lieu. 
Gln Trp 
D NO 14 
H: 2OO 
PRT 
SM: Porc 
SS 
RE: 
NFORMAT 
RE: 
ON: (58) 
NFORMAT 
RE: 
ON: (94) 
NFORMAT 
RE: 
&223> OTHER 
ON: (164 
NFORMAT 
<4 OO SEQUENCE: 14 
Met Leu Gly 
1. 
Lell 
2O 
Asn 
35 
Glu 
SO 
Glu 
65 
Ala 
85 
Ser 
OO 
Ala 
15 
Lell 
45 
le 
65 
Trp 
Xaa 
Luell 
Thir 
Luell 
Thir 
Wall 
Asn 
Luell 
Glu 
Arg 
Ala 
Cys 
Ser 
Asn 
Phe 
Thir 
Ala 
Wall 
Glu 
Lys Cys 
5 
Ile Wall 
Ser Ser 
Gly Thr 
Wall Ile 
Thir Ser 
Gly Tyr 
Ala Lieu. 
Met Ser 
Thr Lys 
Xaa Gly 
Wall Lieu. 
Gln Trp 
KEY: misc 
KEY: misc 
KEY: misc 
Trp 
135 
Gly 
150 
Lys 
17O 
Asp 
185 
Gly 
2 OO 
ine 
Lel 
25 
His 
4 O 
Asp 
55 
Phe 
70 
His 
9 O 
yr 
OS 
Ala 
2O 
rp 
35 
Gly 
2 OO 
47 
Arg 
Gly 
Wall 
Gly 
Arg 
Tyr Ala Cys 
Lieu. Tyr Arg 
Glu Wall Glu 
Ser 
Pro 
Wall Ala 
Thir 
14 O 
Trp 
155 
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Arg Tyr Thr Asn 
Arg Ser Pro Val 
Gly His Lieu. Ile Asp 
17s 
Thir 
190 
Pro Ile Thr Arg 
Phe 
Ile 
160 
Luell 
Wall 
reproductive and respiratory syndrome virus 
KEY: misc feature 
ON: (34) . . (34) 
ON: Xaa 
feature 
... (58) 
ON: Xaa 
feature 
... (94) 
ON: Xaa 
feature 
) . . (164) 
ON: Xaa 
Thir 
Phe 
Lell 
Trp 
Pro 
Phe 
His 
Ala 
Arg 
Lys 
Wall 
Gly 
Arg 
Ca 
Ca 
Ca 
Ca 
Ala 
Glin 
Luell 
Wall 
Luell 
Gly 
Luell 
Luell 
Glu 
Ser 
Pro 
loe 
loe 
loe 
loe 
Gly 
Phe 
Luell 
Asn 
Luell 
Asp 
Arg 
Ile 
Ser 
Tyr 
Wall 
Ala 
any 
any 
any 
any 
Cys 
Ala 
Ile 
Xaa 
Thir 
Thir 
Glu 
Ala 
naturally 
naturally 
naturally 
naturally 
Ala 
3 O 
Tyr 
45 
Lys 
6 O 
His 
7s 
Wall 
95 
Wall 
1O 
Ser 
Lell 
Asn 
Phe 
Ile 
Gly 
Lell 
Wall 
Arg 
Arg 
His 
Pro 
Glin 
Wall 
Lell 
Asp 
Wall 
Lell 
Ser 
Ile 
Ser 
Lell 
Wall 
Luell 
Asn 
Thir 
Trp 
Ser 
Xaa 
Ser 
Arg 
Thir 
Pro 
Ile 
Thir 
occurring 
occurring 
occurring 
occurring 
Pro 
15 
Ala 
Ile 
Ala 
Thir 
Ile 
Luell 
Asn 
Wall 
Asp 
Arg 
amino 
amino 
amino 
amino 
Phe 
Ser 
Wall 
Gly 
8O 
Wall 
Ala 
Phe 
Ile 
160 
Luell 
Wall 
acid 
acid 
acid 
acid 
48 
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<210 SEQ ID NO 15 
<211 LENGTH: 2O1 
&212> TYPE: PRT 
<213> ORGANISM: Porcine reproductive and respiratory syndrome virus 
<4 OO SEQUENCE: 15 
Met Arg Cys Ser His Lys Lieu. Gly Arg Phe Lieu. Thr Pro His Ser Cys 
1. 5 1O 15 
Phe Trp Trp Leu Phe Leu Lleu. Cys Thr Gly Lieu Ser Trp Ser Phe Ala 
2O 25 3 O 
Asp Gly Asn Gly Asp Ser Ser Thr Tyr Glin Tyr Ile Tyr Asn Lieu. Thr 
35 4 O 45 
Ile Cys Glu Lieu. Asn Gly Thr Asp Trp Leu Ser Ser His Phe Gly Trp 
SO 55 6 O 
Ala Val Glu Thr Phe Val Lieu. Tyr Pro Val Ala Thr His Ile Leu Ser 
65 70 7s 8O 
Lieu. Gly Phe Lieu. Thir Thr Ser His Phe Phe Asp Ala Lieu. Gly Lieu. Gly 
85 9 O 95 
Ala Val Ser Thr Ala Gly Phe Val Gly Gly Arg Tyr Val Lieu. Cys Ser 
OO OS 1O 
Val Tyr Gly Ala Cys Ala Phe Ala Ala Phe Val Cys Phe Val Ile Arg 
15 2O 25 
Ala Ala Lys Asn. Cys Met Ala Cys Arg Tyr Ala Arg Thr Arg Phe Thr 
3O 35 4 O 
ASn Phe Ile Val Asp Asp Arg Gly Arg Val His Arg Trp Llys Ser Pro 
45 SO 55 160 
le Val Val Glu Lys Lieu. Gly Lys Ala Glu Val Asp Gly Asn Lieu Val 
65 70 7s 
Thir Ile Llys His Val Val Lieu. Glu Gly Wall Lys Ala Glin Pro Lieu. Thir 
8O 85 90 
Arg Thir Ser Ala Glu Gln Trp Glu Ala 
95 2 OO 
<210 SEQ ID NO 16 
<211 LENGTH: 15414 
&212> TYPE: DNA 
<213> ORGANISM: Porcine reproductive and respiratory syndrome virus 
<4 OO SEQUENCE: 16 
atgacgtata ggtgttggct C tatgc.catg acatttgtat tt Caggagc tigc gaccatt 6 O 
ggtacagc cc aaaact agct gcacagaalaa CCCCttctg tacagc cct Ctt cagggga 12 O 
gcttaggggit ctdtcc ctag caccittgctt coggagttgc actgctttac gigt ct ct coa 18O 
accctittaac catgtctggg at acttgatc ggtgcacgtg Caccc.ccaat gcc agggtgt 24 O 
titatggcgga gggccaagttc tactgcacac gatgtct cag tic acggtct Ctcct tcct c 3OO 
tgaatctoca agttcCtgag Cttggagtgc tigggcctatt ttacaggc.cc galaga.gc.cac 360 
tccggtggac gttgcc acgt gcatt cocca Ctgttgagtg Ctcc.ccc.gcc ggggcctgct 42O 
ggctttctgc gat ctitt.cca attgcacgaa taccagtgg aaacctgaac tittcaacaaa 48O 
gaatggtgcg ggtcgcagct gagatttaca gagc.cggcca gct cacc cct gcagt cttga 54 O 
aggctic taca agtttatgaa cqgggttgcc gctgg taccc tatagt cqga Cctgtc.cctg 6OO 
gagtggcc.gt ttittgccaac tocct acatg tagtgataa acctttc.ccg ggagcaactic 660 
atgtgctaac caacct gcca citccc.gcaga gqcctaagcc tdaag actitt togc ccttittg 72 O 
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&212> TYPE: DNA 
<213> ORGANISM: synthetic 
<4 OO SEQUENCE: 26 
gtcggcc.gcg acttacct tt agag 24 
10 
What is claimed is: 
1. A composition comprising a polynucleotide encoding a 
hypoglycosylated North American PRRSV GP5 polypeptide 
variant wherein at least one N-linked glycosylation site cor 
responding to asparagine 51 in a reference GP5 protein of 
SEQID NO: 1 is inactivated by mutation, and a therapeuti 
cally acceptable carrier. 
2. The composition of claim 1, wherein said polynucle 
otide comprises an infectious North American PRRSV RNA 
molecule. 
3. The composition of claim 1, wherein said polynucle 
otide comprises a DNA molecule that encodes an infectious 
North American PRRSV RNA molecule. 
4. The composition of claim 1, wherein said polynucle 
otide comprises a DNA molecule wherein a promoter active 
in mammalian cells is operably linked to said polynucleotide 
encoding said hypoglycosylated North American PRRSV 
GP5 polypeptide variant. 
5. The composition of claim 4, wherein said promoter is a 
CMV promoter. 
6. The composition of claim 1, wherein said N-linked 
glycosylation site is inactivated by replacing a codon encod 
ing said asparagine 51 with a codon encoding an amino acid 
other than asparagine. 
7. The composition of claim 6, wherein said codon encod 
ing an amino acid other thanasparagine encodes analanine or 
a glutamine residue. 
8. The composition of claim 1, wherein said polynucle 
otide encodes a hypoglycosylated North American PRRSV 
GP5 polypeptide variant protein wherein both of said 
N-linked glycosylation sites corresponding to asparagine 34 
and asparagine 51 in a North American reference GP5 protein 
of SEQID NO:1 are inactivated. 
9. The composition of claim 8, wherein both of said 
N-linked glycosylation sites are inactivated by replacing 
codons encoding said asparagine 34 and said asparagine 51 
with codons encoding an amino acid other than asparagine. 
10. The composition of claim 9, wherein said codons 
encoding another amino acid encode either an alanine or a 
glutamine residue. 
11. The composition of claim 8, wherein one of said 
N-linked glycosylation sites is inactivated by replacing one 
codon encoding said asparagine 34 or said asparagine 51 with 
a codon encoding an amino acid other than asparagine. 
12. The composition of claim 1, wherein said therapeuti 
cally acceptable carrier is selected from the group consisting 
of a protein, a buffer, a surfactant, and a polyethylene glycol 
polymer, or any combination thereof. 
13. The composition of claim 1, wherein said composition 
further comprises at least one adjuvant. 
14. The composition of claim 13, wherein said adjuvant is 
selected from the group consisting of aluminum hydroxide, 
Quil A, an alumina gel Suspension, mineral oils, glycerides, 
fatty acids, fatty acid by-products, mycobacteria, and CpG 
oligodeoxynucleotides, or any combination thereof. 
15. The composition of claim 13, wherein said composi 
tion further comprises a second adjuvant is selected from the 
15 
25 
30 
35 
40 
45 
50 
55 
60 
65 
group consisting of interleukin 1 (IL-1). IL-2, IL4, IL-5, IL6. 
IL-12, gamma interferon (g-IFN), cell necrosis factor, MDP 
(muramyl dipeptide), immuno stimulant complex (ISCOM), 
and liposomes. 
16. The composition of claim 1, wherein said polynucle 
otide comprises a viral vector selected from the group con 
sisting of a vaccinia virus vector, a herpes simplex viral vec 
tor, an adenovirus vector, an alphavirus vector, and a TGEV 
Vector. 
17. An isolated polynucleotide encoding a hypoglycosy 
lated North American PRRSV GP5 polypeptide variant 
wherein at least one N-linked glycosylation site correspond 
ing to asparagine 51 in a reference GP5 protein of SEQ ID 
NO:1 is inactivated by mutation. 
18. The isolated polynucleotide of claim 17, wherein both 
N-linked glycosylation sites corresponding to asparagine 34 
and asparagine 51 in SEQID NO:1 are inactivated. 
19. The isolated polynucleotide of claim 17, wherein said 
polynucleotide comprises an infectious North American 
PRRSV RNA molecule. 
20. The isolated polynucleotide of claim 17, wherein said 
polynucleotide comprises a DNA molecule that encodes an 
infectious North American PRRSV RNA molecule. 
21. The isolated polynucleotide of claim 17, wherein said 
polynucleotide comprises a DNA molecule wherein a pro 
moter active in mammalian cells is operably linked to said 
polynucleotide encoding said hypoglycosylated North 
American PRRSV GP5 polypeptide variant. 
22. The isolated polynucleotide of claim 21, wherein said 
promoter is a CMV promoter. 
23. The isolated polynucleotide of claim 17, wherein said 
N-linked glycosylation site corresponding to asparagine 51 is 
inactivated by replacing a codon encoding said asparagine 51 
with a codon encoding an amino acid other than asparagine. 
24. The isolated polynucleotide of claim 23, wherein said 
codon encoding another amino acid encodes an alanine or a 
glutamine residue. 
25. The isolated polynucleotide of claim 17, wherein an 
N-linked glycosylation site corresponding to asparagine 34 in 
a reference GP5 protein of SEQID NO:1 is inactivated. 
26. The isolated polynucleotide of claim 25, by replacing a 
codon encoding said asparagine 34 with a codon encoding an 
amino acid other than asparagine. 
27. The isolated polynucleotide of claim 25, wherein said 
codon encoding another amino acid encodes an alanine or a 
glutamine residue. 
28. The isolated polynucleotide of claim 25, wherein one of 
said N-linked glycosylation sites is inactivated by replacing 
one codon encoding said asparagine 34 or said asparagine 51 
with a codon encoding an amino acid other than asparagine. 
29. The isolated polynucleotide of claim 17, wherein said 
polynucleotide comprises a viral vector selected from the 
group consisting of a vaccinia virus vector, a herpes simplex 
viral vector, an adenovirus vector, an alphavirus vector and a 
TGEV vector. 
